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Avian influenza (AI) and avian infectious bronchitis (IB) are two highly contagious diseases 
affecting respiratory systems in avian species, caused by avian influenza virus (AIV) and infectious 
bronchitis virus (IBV), respectively. AI and IB cause enormous economic losses to the poultry 
industry. Vaccination is the cornerstone in controlling AI and IB. However, the development of 
effective vaccines for these two diseases is challenging due to the highly mutable nature of these 
two RNA viruses. We used our self-assembling protein nanoparticles (SAPNs) to display the 
conserved influenza (M2e and Helix C) and IBV (the second coiled-coil sequence of S2 protein 
and receptor binding domain) antigens in their native oligomerization states. To further improve 
the immunogenicity of the SAPNs, we designed and incorporated the TLR5 agonist flagellin into 
the SAPNs to generate self-adjuvanted SAPNs. Chickens vaccinated with the self-adjuvanted 
SAPNs induce significantly higher levels of antibodies than those with unadjuvanted SAPNs and 
show higher cross-neutralizing activity compared to a commercial inactivated virus vaccine. 
Vaccinated chickens with the AI SAPN are protected from challenge with a highly pathogenic 
avian influenza. Our IBV vaccine prototypes have demonstrated the ability to induce high levels of 
antibodies, significantly potentiate immune memory, and significantly reduced tracheal virus 
shedding 2 and 4 days post challenge with IBV M41 strain. Lower histopathologic scores were 
observed in the vaccinated group versusthe nonvaccinated group. These data presented in this work 
indicate that we have successfully designed and implemented our self-adjuvanted SAPNs for use 
as vaccine candidates for avian influenza and infectious bronchitis. We have demonstrated self-
adjuvanted SAPN vaccine prototypes are protective against challenge bythe two avian respiratory 
viral pathogens. It is suggested that they could be used as a stand-alone – or possibly even better – 
as an additional component 
Jianping Li-University of Connecticut, 2018 
to an established AI or IB vaccine to broaden the protection of the vaccine. Furthermore, with these 
findings in mind, we can expand our self-adjuvanted SAPN technology for use in many different 
diseases that have been traditionally difficult to develop effective vaccine candidates for including 
malaria, tuberculosis, HIV and many more. 
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Chapter 1. Literature review and general introduction 
1.1 Avian viral respiratory diseases 
US poultry industry is the biggest one in the world. The total value of poultry production 
combining eggs, broilers and turkeys was 48 billion according to the US Department of Agriculture 
in 2015. Avian viral respiratory diseases continue to cause enormously economic losses for the 
poultry industry. The viral diseases frequently found in avian species are infectious bronchitis (IB), 
avian influenza (AI), Newcastle disease (ND), infectious laryngotracheititis (ILT) and 
pneumovirus. AI and IB are the most contagious and predominant diseases affecting respiratory 
systems in avian species. Vaccination is the cornerstone in controlling AI and IB. In this chapter, 
the progress in IB and AI research is reviewed. We address current issues in vaccine development 
for controlling these two diseases, and discuss peptide-based nanoparticles as a potential alternative 
in solving these problems in vaccinology.  
 1.2 Avian influenza and avian influenza viruses (AIV) 
1.2.1 Epidemiology of AI  
Avian influenza is a zoonotic viral disease, known informally as bird flu. The disease is 
caused by avian influenza type A virus, which belongs to the family of Orthomyxoviridae. Wild 
aquatic birds such as ducks, geese, swans, gulls, terns and shorebirds are recognized as natural 
reservoirs for all subtypes of AIV(1). Low pathogenic avian influenza viruses (LPAIV) primarily 
replicate in epithelial cells lining the intestinal tract in ducks, which could result in excretion in 
feces with high virus concentrations(2). The potential of persistence of viruses shed into water has 
been demonstrated to be infectious up to 4 days at 22 °C and 30 days at 0 °C(2). Virus strains have 
been isolated from surface waters from different areas around the world(3-5). The survival period 
in a water environment is affected by temperature, salinity and pH of the water(6). Birds living in 
		 2 
aquatic environments may have a high prevalence of AIV infections via fecal-oral route of 
transmission when water is contaminated with AIV viruses. Migratory avian Anseriformes and 
Charadriiformes are known to be responsible for carrying AIV pathogens to spread LPAI 
internationally and even intercontinentally during multiple stops in aquatic habitats in the course 
of their long-distance migration. Extensive surveillance studies have shown that wild ducks in 
North America have a peak frequency of virus isolation up to 60% in Fall at marshaling sites before 
southbound migration and have as low as ~0.25% frequency in spring while they return back. 
Frozen lakes also contribute to the perpetuation of AIV during the winter(7). National AIV 
surveillance programs on wild birds throughout the world demonstrated different subtypes of AIV 
could co-circulate in aquatic birds in wild habitats(8-13).  
 Several modes of transmission in figure 1 (14) have been demonstrated to spread virus 
among species.  The virus is spread from aquatic avian species to domestic ducks and other 
domestic poultry via fecal-oral transmission in contaminated water. Once AIV infection is 
established in domestic poultry species, the transmission of virus among domestic birds could be 
very rapid by airborne route, direct contact with infected birds, contaminated surfaces and 
dispersing dust particles(15, 16).  Eventually, it would lead to devastating outbreaks. Table 1.1 
summarized striking outbreaks in history during the past decade in North America and around the 
world. Virus could also be less frequently transmitted to mammals such as mice and ferrets(17), 
pigs(18), horses(19), sea mammals (whale (20), seals(21) and minks(22)), and to humans in some 
sporadic cases. The transmission of virus from avian species to humans typically requires an 
intermediate host, usually pigs, for virus adaption undergoing multiple events of viral gene 
mutations and reassortments(23). Direct spread of virus from avian to humans was first observed 
during an H5N1 outbreak in 1997 in Hong Kong (24) and was also seen in a recent outbreak of 
H7N9 during 2013-2015 in eastern China(25). Table 1.2 documents some human cases of 
infections by AIV around the world during past decades.  
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Figure 1. 1 Transmission of avian influenza A virus among hosts.  
AIV in natural reservoir spreads to domestic birds and subsequently either replicates in 
intermediate mammalian host, i.e, pigs, or directly transmits to humans.  
Table 1.1 Outbreaks of AIV in North America during past decade. 
AI strain Year/Location Reference 
H7N8 2016/Indiana, US USDA 
H7N2 2016/New York, US CDC (one human infection) 
H5N2 2014/2015/US, Canada (26) 
H7N3 2012/Mexico (27) 
H5N2 2004/Texas, US (28) 
H7N3 
H7N2 
2004/B.C., Canada 
2003/New York, US 
(29, 30) (Two human cases) 
(29) 
H7N2 2002/Virginia, US (30) 
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Table 1.2 Overview of human infections with H5 and H7 avian influenza around the world.  
AI strain Year/Location Cases/Fatalities Reference 
H5N1 1997/Hong Kong 18/6 (24) 
 2004-2006/Vietnam 97/26 (31) 
 2005-2008/Indonesia 127/103 (26, 32) 
 2003-2013/China 43/30 (33) 
 2004-2006/Thailand 25/17 (34) 
 2006-2009/Egypt 
2014-2015/ Egypt 
63/24 
165/51 
 (35, 36) 
(36) 
H5N6 2014/China 2/1 (37) 
H7N2 2016/US 1/0 CDC 
H7N3 2004/Canada 2/0 (29) 
H7N7 2003/Netherland 89/1 (38) 
H7N9 2013-2015/China 665/229 WHO 
    
    
 
1.2.2 Clinical signs and pathological findings 
Infection with avian influenza causes disease that could be either mild or rapidly fatal. The 
severity of clinical signs and lesions is dependent on the strain. Birds infected with low pathogenic 
strains usually show no clinical signs and low mortality. In domestic poultry like chickens and 
turkeys, infections of LPAI may cause mild respiratory signs manifested by sneezing, coughing, 
nasal and ocular discharge, and sinusitis. Dropping egg production is common in infected layers. 
Infection with highly pathogenic AI viruses (HPAI) in poultry causes severe systemic disease with 
high mortality up to 100% in few days. No clinical signs could be observed before death in peracute 
cases. In severely acute cases of HPLAI, birds show depression, cyanosis of comb and wattle, 
edema of head, bloody oral and nasal discharge, discoloration of shank and feet, greenish diarrhea 
and central nervous impairment. Gross pathological lesions of infections by LPAI and HPAI in 
birds are detailed in table 1.3.  
In human cases of AI disease, clinical symptoms are manifested by fever, sore throat, 
coughing, muscle ache, vomiting, rhinorrhea, diarrhea, loss of appetite, right-upper abdominal pain, 
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congested oropharynx and bilateral pneumonia(39). Pathological findings suggested typical human 
flu-like pneumonia with lesions, which include lymphocyte infiltration, fibrous exudates and red 
cells in alveolar space, vesicular congestion and proliferation of fibroblasts. Hepatic necrosis and 
acute tubular necrosis are also observed in some human cases of AI infection(40).  
Table 1. 1 Gross lesions of LPAI and HPAI(41). 
LPAI HPAI 
• Diffuse epithelial cell hyperplasia in 
tracheal mucosa 
• Infiltration of lymphocytes in 
submucosa 
• Inflammatory cellular exudate, fibrin 
and cellular debris in tracheal lumen 
• Diffuse lymphocytic pneumonia 
• Necrosis in spleen, cloacal bursa, 
thymus and kidney 
• Lymphoid aggregation in kidney 
• Enteritis 
• Brain lesions: diffuse lymphocytic 
perivascular cuffing, multifocal 
gliosis, neuronal degeneration, 
lymphocytic meningitis and 
cerebellum 
• Heart lesions: vacuolization of 
myocardial cells, diffuse histiocytic 
cellular infiltration between muscle 
fibers, coagulative necrosis and 
fibrosis.  
• Lymphoid organs (thymus and bursa): 
lymphocyte depletion and necrosis, 
reduced in size 
• Multifocal necrosis in kidney 
• Pale, white necrotic pancreas 
• Catarrhal tracheitis, severe pneumonia  
  
 
1.2.3 AIV structure 
AIV is an RNA virus shielded with an envelope that is derived from the infected host membrane 
during replication when progeny viruses are budding from the host cells. It has a roughly spherical 
shape with a size range from 80-120nm in diameter. AIV has eight segments of single-stranded 
RNA genes of negative polarity. They encode 10 viral structural and non-structural proteins. Genes 
of segment 1-3 are the three largest ones and encode basic polymerase protein 2 (PB2), basic 
polymerase protein 1(PB1) and acid polymerase protein (PA), which participate the transcription 
of viral mRNAs. They are associated with each segment of RNA genes as well as nucleoproteins 
and form a ribonucleoprotein (RNP) complex. The fourth gene segment is translated into the 
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glycoprotein hemagglutinin (HA), which is a spike protein with a rod-like shape anchored in the 
membrane. Binding to a host cellular sialic acid by HA initiates infection of influenza virus. HA is 
the primary antigenic surface protein to which the host antibody responses are targeted, especially 
neutralizing antibody responses. Therefore, HA is a predominant target for vaccine design. The 
fifth gene segment generates the nucleoproteins (NP), which entangle and protect viral RNA in a 
form of nucleocapsid.  The sixth gene segment generates the mushroom-shaped neuraminidase 
(NA), which is responsible for the cleavage of sialic acid binding allowing the release of mature 
viral particles. The seventh gene segment generates two products, matrix protein 1 (M1) and matrix 
protein 2 (M2). M1 serves as an assembly scaffold during replication and M2 is an ion channel that 
is responsible for membrane fusion with the endosome for uncoating of the viral capsid.  The eighth 
gene segment makes two product proteins by alternative splicing, non-structural protein 1 (NS1) 
and non-structural protein 2 (NS2 or NES). NS2 is a nuclear export signal responsible for the 
relocation of viral RNP complex, which is regulated by NS1 protein. The functions of structural 
and non-structural proteins of influenza A viruses are summarized in table 1.4.  
Table 1. 2 Genes of AIV and their functions 
Segment gene 
(numbers of 
nucleotides*) 
Gene product 
(numbers of amino 
acid residues*, aa) 
Function (References) 
1(2273) Basic PB2 (757) Transcribe viral genomic RNA(42, 43) 
2 (2228) Basic PB1 F1 (757), 
N40 (718) and PB1-
F2 (90) 
PB1 F1 interacts with PA and PB2, and 
participates in the elongation during vRNA 
replication; N40, unknown function; PB1-F2 
targeting mitochondria and triggers 
mitochondria-mediated apoptosis in host 
cells(44-46).  
3 (1187) PA (716) Bound to PB1 to assemble RNP, and maintains 
viral infectivity (47).  
4 (1754) HA (591) Binding to host sialic acid receptor and membrane 
fusion in virus entry(48); 
5 (1528) NP (498) Binding to viral RNA, formation of RNP 
complex, which is pivotal to RNA replication(49) 
6 (1376) NA (480) Cleaves host sialic acid for virus budding during 
maturation and provides signal function in 
translocation(50).  
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7 (1027) M1 (252) and M2 
(97) 
M1 participates in assembly of influenza virion by 
binding to RNP core as well as associating virion 
NS2 protein; M2 is an iron channel and mediates 
uncoating of viral capsid to release RNA genome 
during infection, shunts pH gradient of trans-
Golgi apparatus to prevent premature 
conformational change of HA (51-54).  
8(838) NS1 (230) and NS2 
(121) 
NS1 has many multifunctions including anti-
interferon, regulation of nuclear export of mRNA 
and inhibition of intracytoplasmic pathogen 
sensor. NS2 is nuclear export signal (55, 56).  
*The length of nucleotides and amino acid residues for each segment was compiled with sequences 
of 95 avian and 306 human influenza virus genomes (57). Numbers of nucleotides and amino acid 
residues may vary in a specific subtype. 
 
1.2.4 AIV classification and nomenclature 
Influenza viruses are divided into four genera, influenza A virus, influenza B virus, 
influenza C virus and influenza D virus based on the antigenic specificity to nucleoproteins. 
Influenza A virus has a wide host range across avian and mammalian species. Influenza B viruses 
are predominantly human strains, which was found to cause infection in a seal(58). Influenza C 
virus causes interspecies transmission between humans and pigs(59). Influenza D virus is distantly 
related to human influenza C virus, which was first isolated from swine in 2011(60). AIV is 
classified into influenza A virus. Further classification of AIV is identified as a subtype that is 
defined by spike glycoproteins hemagglutinin (HA) and neuraminidase (NA) on the viral surface, 
for example, H5N1. Currently, 18 subtypes of hemagglutinin and 11 subtypes of neuraminidase 
have been discovered(61). Influenza A viruses could also be classified into two major groups based 
on the antigenic properties of HA, group 1 and group 2 influenza viruses. Group 1 virus contains 
H1, H2, H5, H6, H8, H9, H11, H12, H13, H16, H17 and H18. Group 2 viruses include H3, H4, H7, 
H10, H14 and H15(62). An isolate can be further defined by a standard nomenclature with 
specification of antigenic type of virus, host of origin, geographical origin, strain number, year of 
isolation and HA and NA subtype information, for example, A/chicken/Hong Kong/220/97/(H5N1) 
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(63). Nonetheless, according to the viral pathogenicity, avian influenza viruses can be divided into 
low pathogenic avian influenza viruses (LPAIV) and highly pathogenic avian influenza viruses 
(HPAIV). The difference between the two is the composition of the cleavage site of a hemagglutinin 
precursor molecule (HA0). LPAIV does not contain a series of basic amino acids at the cleavage 
site of HA0, in which the cleavage of HA0 into HA1 and HA2 is restricted to protease in respiratory 
tract and intestinal organs. Therefore, it leads to mild localized disease outcome. In contrast, 
HPAIV contains a series of basic amino acids at the cleavage site of HA0 so that can be recognized 
by protease in multiple organs in the host and subsequently cause systemic lethal diseases(64).  
1.2.5 AIV replication and pathogenesis 
1.2.5.1 Virus entry 
The sialic acid receptor has been demonstrated to be a glycoprotein receptor of HA that is 
responsible for virus entry initiating the infection of influenza viruses. Sialic acid, N-
acetylneuraminic acid (Neu5Ac), links nine carbon monosaccharides to the penultimate galactose 
residue on the glycan receptor via either α-2, 3 or α-2, 6 linkage configurations(65). In avian 
species, the presence of α-2, 3 and α-2, 6 sialic acid receptors were found on surfaces of epithelial 
cells lining the respiratory tract and intestinal tracts(66). Influenza viruses of avian origin 
preferentially bind to α-2, 3 sialic acid receptors for virus entry whereas viruses of mammalian 
origin preferentially bind to α-2, 6 sialic acid receptors. It had been thought for decades that this 
difference is attributed to host specificity restriction and inefficiency of interspecies transmission. 
Pigs bearing α-2, 3 and α-2, 6 sialic acid receptors serve as mixing vessels for reassortment of 
different strains, in which this process adapts avian influenza viruses to further spread in 
mammalian species(67). However, direct transmission of H5 and H7 AIV from avian species to 
humans led to the discovery of the presence of α-2, 3 in human lower respiratory tract explaining 
the observation of pneumonia in human infections by H5N1 and H7N9(68, 69).  
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Influenza binds sialic acid receptors and initiates the engulfment of virus particles through 
clathrin-mediated endocytosis as well as macropinocytosis(70). After internalization, an endocytic 
vesicle is formed with the inclusion of influenza virus particles. The vesicles are subsequently fused 
with endosomal compartments resulting in the delivery of virus particles into the endosome 
lumen(71, 72).  
1.2.5.2 Membrane fusion and viral capsid uncoating 
The low pH (pH 5-6) environment in endosomes allows a condition for opening the M2 
ion channel of influenza virions constrained within endosomes. Protons are transported across the 
viral membrane into the viral lumen from the endosome via the M2 ion channel so that the virion 
can be acidified(54). Upon acidification, influenza HA undergoes an acid-induced conformational 
change leading to the exposure of fusion peptides buried in the stem of HA trimers(73). Exposed 
fusion peptides will insert into endosomal membrane and further facilitate close contact of the 
membranes(74). While viral and endosomal membranes are fused, vRNP will be dissociated from 
M1 and released into cellular cytosol allowing viral entry into the host nucleus(75).  
1.2.5.3 Replication and translation 
The released RNP complexes are subsequently transported to the nucleus with the aid of 
its associated NP proteins containing nuclear localization sequences (NLS). There are at least two 
nuclear localization sequences in the RNP complex, which are NLS1 (residues, 3-13) and NLS2 
(residues, 198-216). NLS1 is necessary for the efficient viral mRNA synthesis whereas NLS2 is 
essential for viral RNA (vRNA) transcription and nuclear accumulation of NP proteins(76). Both 
NLS1 and NLS2 are essential to nuclear transportation of the RNP complex in the presence of 
proteins: heterodimeric karyopherin, GTPase Ran and p10(77). RNA-dependent RNA polymerases 
of the RNP complexes transcribe and replicate negative sense viral RNA after translocation of the 
RNP complexes producing three types of RNAs, including viral mRNA used for viral protein 
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translation in cytoplasm, complementary positive-sensed RNAs (cRNAs) that are sequestered in 
the nucleus and serve as template for vRNAs’ synthesis, and negative-sensed small RNA which 
function in switching transcription to replication(78). Viral mRNAs will be exported to the 
cytoplasm for translation of viral proteins once they are transcribed(79). New translated proteins 
PB1, PB2, PA, NP that are essential to transcription of viral vRNA will participate in the process 
of replication of the vRNA genome. The nascent proteins M1, NEP and NS1 are also transported 
back to the nucleus for further escorting the exportation of progeny vRNA out of the nucleus to the 
budding patches under the cellular membrane(80, 81). Synthesized HA, NA and M2 proteins in 
cytoplasm are further processed in the endoplasmic reticulum to fold into trimeric or tetrameric 
conformations and be glycosylated(82). Subsequently, they are trafficked to the budding site for 
the assemble of progeny viral particles through the Golgi apparatus. Further modification of these 
proteins like introducing disulfide bonds and modifying oligosaccharide side chains also takes 
place in the Golgi apparatus during the trafficking. To prevent inducing premature conformational 
change of HA proteins by the acid environment of the Golgi apparatus, abundantly expressed M2 
proteins are located at the trans-Golgi site and serve as a proton pump to shunt the pH gradient of 
the Golgi apparatus via their functions of ion channel during influenza virus infection(54). Upon 
the presence of entire viral proteins in the cytoplasm, NP proteins and polymerases (PB1, PB2 and 
PA) will interact with the newly synthesized progeny vRNA to form the RNP complex.  
1.2.5.4 Virus assembly and release of progeny viruses 
The Matrix protein is the major driving force in influenza virus budding(83). On one hand, 
M1 proteins act as a scaffold interacting with cytoplasmic tail and transmembrane domains of HA 
and NA proteins that are sorted exterior the cellular membrane on the apical side of epithelial cells. 
HA and NA are viral proteins intrinsically associated with lipid raft domains of the cellular 
membrane, driving the formation of a budding zone and the initiation of the budding process(84). 
Binding to cytoplasmic tails of HA and NA allows M1 to associate lipid raft membrane leading to 
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polymerization of M1 in the budding zone(85).  M2 protein is also sorted to the apical side of 
epithelial cells. This interaction forms budding patches at the apical side of the cells. On the other 
hand, M1 proteins also function as an inhibitor to prevent nuclear translocation of new progeny 
vRNPs by interacting with vRNPs(80). M1 proteins direct progeny vRNPs to the budding patches, 
in which M1 forms a bridge between the viral envelope and vRNP(86). Packing of segmented genes 
is not randomly selected but under a specific mechanism. Although the exact mechanism for 
genome packing is not fully elucidated, evidence points out that the packing process is the selection 
of one copy of each vRNA(87). Reassortment of genomes takes place during the assembly process 
when the host is infected with two or more different influenza virus strains. Assembly of virus 
blocks the completion of HA mediated budding. Once assembly is completed, budding of progeny 
virus is triggered(88). At the final stage of budding, M2 proteins alter membrane curvature in a 
cholesterol-dependent manner induced by M2 amphipathic helix domains of its cytoplasmic tail. 
This domain functions in membrane scission and virion release, in which the process is independent 
of host ESCRT (endosomal sorting complexes required for transport) (89). After budding, the 
progeny virions are attached to the sialic acid glycoprotein receptors bound to viral HA proteins. 
Cleavage of sialic acid binding by NA permits the release of progeny viruses(90).  
1.2.6 Immune responses to AIV infection 
1.2.6.1 Innate immune responses to AIV infection 
The innate immune response is considered the first line of defense against microbial 
infections. Germ-line encoded pattern recognition receptors (PRR) have been demonstrated to 
sense microbial pathogens initiating the innate defense machinery against microbial infection(91). 
Endosomal toll-like receptors (TLR3/7), membrane-bound PRR, have been shown to recognize 
influenza virus genomic RNA(92, 93). Cytoplasmic PRRs, the nucleotide-binding domain and 
leucine-rich-repeat-containing (NLR) family 3 (NLRP3) (94), the retinoic acid inducible gene I 
(RIG-I) and melanoma differentiation factor-5 (MDA5) (95), and DNA-dependent activator of 
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interferon regulatory factors (DAI) are essential to the recognition of influenza viral RNA during 
replication in infected cells and to mediate the production of anti-viral cytokines IL-1β and 
interferon(96). Subsequent innate signal cascade upon pattern associated recognition augments the 
recruitment of natural killer cells (NK cells) and neutrophils (mammal species) in the sites of 
infection, and activation of complement systems, which would further fight against AIV 
infection(97, 98). In the meantime, innate immune signals will further trigger the second arm of the 
immune system-the adaptive immune responses against AIV infection.  
LPAIV cause no or mild disease in avian species. Infection of LPAIV induces production 
of pro-inflammatory cytokines including IL-2, IL-6, IL-8, IFN-α, IFN-β, and IFN-γ(96, 99). 
HPAIV can systemically replicate resulting in mortality in infected avian species. Chickens are 
more susceptible to HPAIV infection than ducks. It is plausibly explained by the fact that ducks 
possess RIG-I detecting uncapped viral RNA and initiating INF production whereas chickens lack 
this counterpart immune sensor molecule(100). In addition, chickens have more pronounced IL-6 
innate immune responses against HPAIV H5N1 infection than ducks(101). Inhibition of STAT-3 
mediated anti-inflammatory functions by HPAIV H5N1 infection in chickens show highly elevated 
pro-inflammatory cytokine responses leading to a “cytokine storm” compared to lower levels of 
induced pro-inflammatory cytokine responses in ducks(102, 103).  
Although hypercytokinemia was also consistently observed in sera of hospitalized patients 
infected with HPAIV either H5N1 or H7N9(104, 105), infection of HPAIV showed a plausible 
profile of innate immune responses in humans. Robust pro-inflammatory cytokine responses of 
TNF and IP-10 in monocyte-derived macrophages were observed. However, the alveolar 
macrophages derived from human lungs have demonstrated HPAIV-induced limited pro-
inflammatory cytokine responses(106, 107). NK cells from influenza-healthy donors have 
demonstrated their role in aiding viral control via the pathway of antibody-dependent cellular 
cytotoxicity (ADCC) (108, 109). However, H7N9 infected patients had prolonged hospitalizations, 
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showing significant expansion of NK cells population(110).  Conversely, some evidence 
demonstrated innate-like cells including innate-like T cells, Vγ9δ2 T cells, NK cells, and mucosal-
associated invariant T cells played essential roles in protecting human lung epitheliums from 
damage (111-113). Therefore, it is essential to understand how microenvironments dictate 
differential immune responses during avian influenza infection.  
1.2.6.2 Adaptive immune responses against AIV infection 
Innate immunity is not sufficient to stop pandemic AI strains. Adaptive immunity is a reliable 
second arm to completely eliminate viral infections. Adaptive immune responses engage the 
activation of B cells and T cells in bone marrow leading to humoral and cell mediated immunity 
with characteristics of immunological memory. Adaptive immunity against AIV infection is 
initiated upon the activation of T cells engaging the recognition of AIV specific antigens presented 
by the major histocompatibility complex (MHC). There are two classes of MHC, MHC I and P, 
engaging peptide antigen binding, processing and presentation. MHC I is associated with CD8+ T 
cells (cytotoxic T cells) (114) whereas MHC P is associated with CD4+ T cells (T helper cells) 
(115). AIV-activated T cells secrete a variety of cytokines and differentiate into subsets of T cells, 
including T helper cells, cytotoxic T cells and regulatory T cells. With the help of the T helper cells, 
B cells are stimulated and are able to mature to produce antibodies targeting the AIV involved. AIV 
activated T and B cells are programed to form subsets of memory cells targeting specific AIV 
epitopes. An ideal vaccine is designed to prime adaptive immunity, on one hand, to stimulate naïve 
B cells to differentiate into memory B cells as well as plasma B cells to produce circulating 
antibodies, on the other hand, to activate AIV specific T cells. These two arms of adaptive immune 
responses will be activated upon the re-exposure of AIV natural infection.  
Although birds lack lymph nodes that actively engage the formation of germinal centers for 
antibody production, birds have been demonstrated to be able to mount humoral responses against 
		 14 
AIV infection, involving AIV antigen processing in cloaca, bursa, cecal tonsils, Meckel’s 
diverticulum, Peyer’s patches, and diffuse mucosal lymphoid tissues(116-118). The Harderian 
gland is a well-described secondary lymphoid organ in chickens, which is located in the paranasal 
area orbiting the eyes(119). It concentrates large numbers of plasma cells secreting antiviral 
IgA(120). Antibody responses directing viral surface proteins HA, NA and M2e are essential to 
protect poultry from AIV infections. Eliciting neutralizing Ig Y against HA blocks entry of AIV 
protected chickens from HPAIV challenge(121). Anti-NA antibodies provided partial protection 
from HPAIV challenge(122). M2e is highly conserved across human and avian influenza viruses, 
showing protection in mice(123-125). Anti-M2e antibodies are not neutralizing but provided 
protection via ADCC mechanism at a low-dose influenza virus challenge(126, 127). Although cell 
mediated immune responses against AIV infection are not well understood in poultry, it has been 
demonstrated that adoptive transfer of CD8+ T cells from H9N2 infected chickens to naïve inbred 
chickens showed cross-reactive protection against H5N1 HPAIV challenge(128). The cross-
reactive protection was closely correlated to pulmonary CD8+ T cells expressing INFγ and αβ1 T 
cell receptors (129)  
Antibody responses against AIV were actively detected in human sera(130, 131). The presence 
of antibodies against AIV is inversely correlated to the clinical outcomes in infected humans. 
Results of serological surveillance conducted during an outbreak of H7N9 infections in humans in 
China in 2014 found that 68.5% of infected patients who survived showed elevated antibody 
response to H7N9 at 14 days post symptom onset whereas only 28.6% of fatal patients showed 
presence of antibodies(132). It has been reported that influenza virus-specific CD8+ cytotoxic T 
cells conferred protection against severe influenza, accelerating viral clearance and host recovery, 
supported by evidence that patients who had more prominent pre-existing influenza-specific CD8+ 
or CD4+ memory T cell pools more rapidly recover from influenza disease(133). Evidence has also 
shown heterosubtypic memory T cell responses against avian H5N1 were elicited in healthy 
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individuals without history of pre-exposure to AIV(134). Recent studies by Wang further 
demonstrated recovery from severe H7N9 disease via mechanisms dominated by CD8+ T cells 
responses. They showed H7N9 infected patients who recovered within 2-3 weeks had more 
prominent H7N9 specific- T cell responses whereas patients with prolonged hospitalization showed 
late recruitment of CD8+/CD4+ T cells. Fatal patients had minimal level of T cell activation(110). 
Therefore, induction of CD8+/CD4 memory by an ideal vaccine is very important in fighting 
against AIV infection.   
 1.3 Avian infectious bronchitis (IB) and infectious bronchitis virus (IBV) 
1.3.1 Overview of IB  
IB is a highly contagious avian respiratory disease of economic importance affecting 
poultry globally. Schalk and Hawn first described the disease in the United States in 1931(135). 
Beaudette and Hudson had isolated the first etiology of the disease by culture in chicken embryos 
in 1936 that was the original infectious bronchitis virus of Massachusetts isolate (136), which 
belongs to the family of Coronaviridae. Chickens are the major natural hosts of IBV. Clinically, 
chickens less than six weeks of age infected with IBV show 100% of morbidity, which is usually 
manifested by respiratory signs including nasal discharge, coughing, sneezing, tracheal rales, 
conjunctivitis, dyspnea and lethargy(137). The mortality rate in young chickens is normally 25-
30% depending on the host immune status, environmental factors and flock ages. Secondary 
bacterial or viral co-infections can exacerbate IB(138). Nephropathogenic IB strains produce less 
respiratory signs, but can cause mortality in young chickens, interstitial nephritis and damage to 
oviduct, leading to marked decrease of egg production and misshaped eggs in layers(139). It is 
impossible for an affected flock to return to the normal production of eggs(140).  
Gross lesions of IB in chickens are congestion and mucous exudate in bronchi and trachea 
observed postmortem. When E. coil complicates IB, there are additional gross lesions including 
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caseous airsacculitis, perihepatitis, pericarditis and cystic oviducts in young chickens(141). 
Infection of nephritic strains produces gross lesions of swollen, pale kidneys in chickens(142, 143). 
Diagnosis of IB infection should be differentiated from other avian respiratory diseases with similar 
clinical signs such as Newcastle disease virus, avian metapneumovirus and infectious 
laryngotracheitis virus. Virus isolation from the field is a definitive method for laboratory 
confirmation of IB disease. Tracheal swab samples or tissues from infected birds can be used to 
prepare homogenates and inoculated into 9-11 day- old embryos for 5-8 days, in which embryos 
exhibit signs of stunting and curling in positive infections(144). In addition, virus isolation has also 
been applied in tracheal organ culture. The growth of IBV virus will cause cessation of cilia 
mobility(145). Virus-neutralization tests performed in chick embryo tracheal organ cultures had 
also been developed as a tool for laboratory confirmation. Positive serum neutralization is expected 
to show less or no ciliostasis in treated epithelium as compared to negative sera treated 
controls(146). In addition to labor-intensive virus isolation, methods such as ELISA, PCR and 
fragment restriction analysis have been largely applied for the rapid diagnosis of IB.   
Vaccination has been the predominant strategy applied to control IB for a half century. 
Live attenuated vaccine is the most commonly used type of vaccine in poultry. It has been largely 
administered by drinking water or spray for mass vaccination in young chickens. Inactivated 
vaccine is restricted to injection in breeder or layers(138). Selection of vaccine strains is under the 
guideline of epidemiological data regarding the prevalence of IBV in a given area. For instance, 
Mass, Ark, JMK, Conn, Delaware and H120 have been used to formulate live attenuated IB 
vaccines in the USA whereas variants M41, 4/91, CR88, Dutch strain 274 and Dutch strain 1466 
have been used to derive live vaccines in Europe. However, current vaccines are not fully protective 
against all IB infection in the field due to the existence of a large number of IBV variants, high 
frequency of point mutation in IBV and recombination between IBV variants and vaccine strains. 
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These issues continuously challenge the development of effective IBV vaccines, highlighting the 
need for alternative IBV vaccines(147).  
1.3.2 IBV-structure, replication in cells and pathogenesis 
1.3.2.1 Structure 
IBV is an enveloped virus characterized by a crown-like appearance of spike glycoproteins 
with 20-nm projections above the virion. It belongs to the gamma coronavirus of family 
Coronaviridae. The virus has a single stranded RNA genome with positive polarity. The genome 
size ranges from 27 to 32kb, making coronavirus the largest RNA virus(148). The viral genes are 
organized in a form of polygenes with a 5’ cap and a poly A tail. The gene 1 located at 5’ UTR 
encodes 15 non-structural proteins, which form a replication complex. Additional 5 non-structural 
genes encoding small non-structural proteins (3a, 3b, 3c, 5a, and 5b) are interspersed among genes 
encoding structural proteins-spike protein (S), small envelope protein (encoded by 3c, E), Matrix 
protein (M) and Nucleoprotein (N). Thus, the polygenes is arranged as 5’ UTR-1a/1ab (polymerase 
genes)-S-3a-3b-E (3c)-M-5a-5b-N-3’ UTR(149).  
The IBV S protein consists of 1,160 amino acids and is a heavily glycosylated 
transmembrane protein. The precursor of S protein is post-translationally cleaved into two domains, 
S1 at the N terminus (520 residues) and S2 at the C terminus (625 residues). A large part of S1 
protein at the N terminus forms an ectodomain of bulb consisting of oligomeric S proteins, 
anchoring on the virion surface. S2 protein is a stalk embedded in the virion membrane through the 
transmemebrane ectodomain(150). The entodomain of S2 contains two heptad repeat sequences 
and a putative class I fusion peptide. The interaction of heptad repeats drives the formation of 
coiled-coil stalk structure, which undergoes low-pH inducing conformational change and mediates 
virus-host cell membrane fusion during virus infection(151). S1 has all receptor binding domains 
and plays an important role in mediating virus entry and is also the major determinant of inducing 
neutralizing antibodies(152).  
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The IBV M protein has a size of approximately 230 amino acids. The protein slightly 
projected a very small portion on the virion surface of an IBV virus. The N terminal domain of M 
protein is glycosylated with unique N-linked polysaccharide rather than with O-linked 
polysaccharide that is commonly found in M proteins of α and β coronaviruses(153). The 
cytoplasmic tail of IBV E and M protein were shown to mediate their interaction(154). The 
transmembrane domain of M protein also interacts with S proteins(155). In addition, there is 
evidence showing that the first membrane-spanning domain of IBV M protein is sufficient to be 
retained in cis-Golgi for post-translational modification of protein(156). These observations 
suggested M protein plays critical role in virus assembly and budding(157).  
The IBV E protein is a product of gene 3c with approximately 100 amino acids. E proteins 
are involved in the formation of virus particles through association with M proteins using their 
cytoplasmic tails(154). E proteins are believed to target a Golgi complex of a host cell and direct 
the release of virus particles during virus replication(158). Ion channel function was also found in 
E protein (159).   
The Nucleoprotein has a size of approximately 420 amino acids. It is a nuclear acid binding 
protein. N proteins are closely associated with IBV genomic RNA to form a ribonucleoprotein 
complex (RNPC) during viral gene transcription, replication, translation and packing of viral 
genome(160). The N protein has been demonstrated to be capable of inducing cytotoxic T cell 
immune responses(161). 
There are 15 nonstructural proteins (Nsp 2-16) encoded by gene 1 of open reading frame 1 
and 2 at 5’ UTR of an IBV genome. They are involved in viral gene transcription and replication 
at different stages. Their functions are described in table 1.5(149). Nonstructural proteins encoded 
by intergenic genes 3a, 3b, 5a and 5b are shown to be less relevant to virus replication but may 
contribute to the virulence of IBV virus(162, 163).  
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Table 1. 3 Nsp proteins and their functions (courtesy modification from Jackwood et al, 
2012(149)) 
Nsp proteins Functions 
Nsp 2 Block host protein synthesis 
Nsp 3 Papain like proteases 
Nsp 4 Anchor replication complex in double membrane 
vesicles (DMVs) 
Nsp 5 Protease cleaved Nsp4-16 
Nsp 6 Membrane-localized proteins in DMVs  
Nsp 7 DMV protein, RNA binding 
Nsp 8 DMV protein, primase 
Nsp 9/10 DMV proteins, replication complex 
Nsp 11/12 RNA-dependent polymerases 
Nsp 13 RNA helicase 
Nsp 14 Exonuclease 
Nsp 15 Endoribonuclease 
Nsp 16 Methyltransferase drives RNA cap formation 
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Figure 1. 2 General structure of an IBV virus.  
S: spike protein, E: envelope protein, M: membrane protein, N: nucleoprotein.  
1.3.2.2 Replication in cells 
 Binding to the cellular receptors of the host cells through the viral glycosylated spike 
protein initiates the infection of IBV. However, the cellular receptor of IBV has not been 
determined. Several putative receptor determinants have been proposed but are quite debatable. 
Winter et al argued that sialic acid was an indispensable determinant for infections of cells by 
IBV(164). Conversely, Yang et al showed sialic acid might play a lesser role in virus-receptor 
complex formation. Instead, they found DC-SIGN, a human C-type lectin, rescued infection of IBV 
mammalian cell lines expressing this molecule, in which IBV are not supposed to establish 
infection due to the tropism to avian cells. Therefore, they hypothesized a proteinaceous lectin-like 
receptor exists in avian cells(165). Although the replication cycle of IBV in cells is not fully 
understood, several genes and features such as double membrane vesicles and Nsp genes have been 
identified similar to other coronaviruses like SARS, which has been extensively studied on its 
replication cycle in cells. Combining the knowledge of replication cycle of the other coronaviruses 
and some unique features in IBV replication like spherules and zippered endoplasmic 
reticulum(166), the whole cycle of replication could be summarized in six steps described in Figure 
1.5 as follows.  
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Figure 1. 3 Replication of IBV in cells.  
1, Virus uncoating; 2, translation of early proteins using virus genomic RNA; 3, transcription to 
synthesize complement RNA and synthesis of progeny genomic RNA; 4, translation of virus 
structural proteins and protein modification in endoplasmic reticulum; 5, Assembly of virus in 
endoplasmic reticulum Golgi complex (ERGIC); 6, budding and release of progeny viruses.  
1.3.2.3 Pathogenesis 
IBV is a highly contagious pathogen, which is spread horizontally by aerosol transmission, 
through contaminants, faecal droplets and drinking water from one flock to another within one or 
two days(137). The incubation period is about 18-36 hours(155). The upper respiratory tract is the 
initial site of infection by IBV where virus replication reaches peak levels at 3 days post 
infection(167).  It causes respiratory signs, the deciliation of the ciliated epithelium and loss of the 
protective cells lining the mucosal surface of the nitrile and trachea. Some nephrogenic and enteric 
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strains distribute systemically in chickens through a brief viremia, affecting kidneys, reproductive 
tract, bursa of Fabricius and enteric tract except the jejunum(167, 168).  Nephrogenic IBV mainly 
replicates in the epithelium cells of the collecting ducts, collecting tubules, distal convoluted 
tubules and Henle’s loops(168). Cell lysis induced by IBV is the direct cause of nephritis and of 
kidney lesions(143). In addition to the replication in kidney tissues, the replication in reproductive 
tract is believed to lead to the decrease of egg production as well as misshaped eggs. The process 
of laying eggs was also demonstrated to be an alternative route of virus transmission in addition to 
the respiratory shedding when a persistent case of IBV infection is present(169).  
1.3.3 Host immune responses of chickens to IBV infection 
Immunization of live virus IBV vaccine in chickens has been a well-established model 
commonly used to investigate the immune responses of chickens to acute IBV infection(155). 
Different aspects of immune responses to IBV have been studied in the chicken model. It has been 
shown that innate and adaptive immunity are actively involved in fighting against acute IBV 
infection in chickens. 
1.3.3.1 Innate immune responses to IBV infection 
Innate immunity is the first line of defense in an immune system. It targets invasive 
pathogens using a set of mechanisms, including physical barriers of skin and mucous, soluble 
factors such as complement molecules, cytokines, chemokines and antimicrobial peptides, and 
leukocytes like heterophils, macrophages and NK cells, etc. Hyperplasia of goblet cells and alveolar 
mucous glands in trachea have been observed in the early phase of IBV infection, in which the 
secreted exudate by these cells limit the progression of infection(170). Mannose-binding lectin 
(MBL), an acute phase protein, was found significantly increased during IBV infections. MBL 
recognizes microbial surfaces through carbohydrate recognition domains, and is able to mediate 
direct opsonization and complement activation by interacting with MBL-associated serine 
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proteases 1 and 2 (MASP-1 or 2) (171). Activation of complement by MBL during IBV infection 
results in inhibiting the propagation of the virus in the trachea in chickens(172). Upregulated gene 
expression of C1q, C1s, anaphylatoxin C3a receptor, and C4 in complement system was also 
reported in the course of IBV M41 infection(173). However, it is still not fully understood how the 
mechanism that infection of IBV activated complement system limits virus propagation.  
The expression of pattern recognition receptors (PPRs), including TLR-1 LA, TLR-1LB, 
TLR-2, TLR-3, and TLR-7, were significantly increased in the tracheal epithelial cells and kidney 
during IBV infection in chickens (173). MDA-5 was shown to be involved in nephropathogenic 
infection of IBV(174). CpG was demonstrated to activate TLR-9 and to be capable of reducing 
viral load in CpG-treated embryos(175). Consequently, the activation of PPRs leads to the cytokine, 
chemokine response and the recruitment of phagocytic leukocytes. Elevated TLR-3 and TLR-7 
were revealed to be associated with production of type I IFN-α, -β, and the pro-inflammatory 
cytokines IL6, TNFSF15, TGFβ, IL-1β and IFNg in trachea and lung of chickens upon IBV M41 
infection(173, 176, 177). Up-regulated MDA-5 was also associated with the production of IFN- 
β(178). Increased chemokine expression was observed in chickens infected with attenuated IBV-
Mass strain including CXCR4, CCR6, chemokine-like receptors/CHEMR23 and CXCLI2. These 
might orchestrate the migration of immune cells to the sites of infection suggested by elevated gene 
expression of integrin β and matrix metalloproteinase(173). Activation of innate immune responses 
to IBV infection is strain-dependent. In contrast to those observations in the infection of IBV Mass 
strain, there was a significant down-regulation of IL-1β and IFNg within chicken trachea in the 
initial stage of infection of IBV Connecticut strain and a following sharp increased expression of 
IL-1β as infection progressed in the later stage(176).  
Upon the activation of innate immune responses by IBV infection, phagocytic leukocytes-
heterophils and macrophages and cytotoxic natural killer cells (NK cells) have been demonstrated 
to be recruited to the sites of infection and to restrict the further propagation of IBV viruses. Fulton 
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et al reported that heterophils could be responsible for destructing IBV-infected cells during IBV 
infection(179). A significant increase in the number of macrophages was observed in spleen, 
trachea and bronchial lumen upon the infection of IBV M41(180, 181). Rapid activation of NK 
cells in lung and blood was also reported along with rapid production of IFNg(182).  
Innate immunity is interconnected to adaptive immunity. However, the mechanisms of 
activating innate immunity by IBV infection in chickens are complex and are not fully understood. 
Further immunological characterization is needed in order to understand the precise signaling 
mechanisms of anti-IBV innate immune response, which would allow the better manipulation of 
its interconnected adaptive immunity against IBV infection.  
1.3.3.2 Adaptive immune responses to IBV infection  
Innate immunity is not able to fully contain the acute infection of a pathogen. The clearance 
of viruses requires further adaptive immunity of humoral and cellular immune responses. Adaptive 
immunity has been extensively evident in antiviral mechanisms against IBV infection in chickens. 
Therefore, it is essential to characterize key signatures of adaptive immune responses against IBV 
infection in chickens, which may provide new opportunities for the improvement of future 
prophylactic strategies to combat the virus infections.  
The knowledge of adaptive immunity against IBV infection began with the concentrated 
studies of humoral responses to IBV vaccination in chickens by measuring IBV-specific antibody 
levels in serum, nasal area, lachrymal fluid and trachea using assays such as enzyme linked 
immunosorbent assay (ELISA), virus neutralization (VN), or HI tests(183, 184). IBV-specific IgM, 
a class of short-lived antibody, was first detectable between 3 and 7 days after primary inoculation 
of IBV M41, reached the peak level at 8 to 10 days p.i with a rapid decline until 21 days p.i. 
Secondary inoculation of IBV M41 elicited an IgM response that had a similar pattern to the 
primary infection. By contrast, IBV-specific IgY, a class of long-lived antibody, first appeared 
between 6 and 7 days post first inoculation of IBV M41, and reached highest concentration at 9 to 
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14 days with gradually declining. It was still detectable at 42 days after primary inoculation. 
Secondary inoculation of IBV M41 was able to significantly boost the titer of IgY into a higher 
level while comparing to the titer after primary inoculation(185-187).  IBV-specific IgA, an 
important antibody in mucosa, was mainly produced by Harderian glands under the eyeballs in 
chickens(188). It has been demonstrated the presence of IgA in lamina propria and in epithelium 
of trachea. It was reported the first appearance of Ig A in lachrymal fluid of chickens at 10 days 
after the ocular inoculation of an attenuated vaccine strain Ark DPI-type IBV(189). Although the 
antibody kinetics were clearly detailed in these studies of humoral responses against IBV acute 
infection in the chicken model, the relationship between antibody responses and protection is 
complicated and is not clear. Winterfield et al demonstrated circulating antibodies does not closely 
correlate with tissue protection(190). However, the presence of high titer of circulating antibodies 
has been showed capable of preventing the spread of viremia to the kidneys of chicken intranasal 
vaccination with H120 IBV after intravenous challenge of the homologous strain(191). Besides, 
systemic IBV-specific IgM was demonstrated well correlated with protective immunity against 
IBV M41(192). Maternal derived antibodies can provide short-lived protection to young chicks 
from IBV infection(193). Local antibody responses were believed playing important role in the 
protection of respiratory tracts against re-infection of IBV virus in chickens, mainly attributed to 
the antibodies produced in the Harderian gland, especially the isotype IgA(194-196). Conversely, 
Gelb et al reported that the protection of tissues was inversely correlated with antibody titers in 
tears of chickens vaccinated with live attenuated vaccine strain IBV M41 after homologous 
challenge with virulent strain IBV M41. It suggested other immunological mechanisms were also 
involved in the local immunity induced in the Harderian gland contributing to tissue protection. 
Therefore, it is particularly important to understand the precise mechanisms mediating humoral 
responses that protect chickens from IBV infection, which may provide valuable guidance in 
improving future vaccine design.  
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In addition to humoral immune responses, cellular immune responses are also very 
important in clearing IBV infection in chickens(197). Cell-mediated immunity against IBV 
infection has been addressed since 1980s. It had been shown by Chubb et al that cytotoxic 
lymphocytes (CTL) are present in the spleen and peripheral blood from IBV-infected 
chickens(198). Timms et al first revealed the ex vivo proliferation of antigen-specific T 
lymphocytes from IBV M41 infected chickens by homologous stimulation(199). Janse et al 
suggested that T cells mediated the protection of trachea where CD4+ and CD8+ cells were present 
in trachea sections from IBV infected chickens(200). Suppression of T-cells in chickens was 
correlated with higher viral load in kidneys than in normal chickens following IBV infection(201). 
However, the direct evidence concerning the role of cell mediated immunity in protection against 
IBV was reported by Seo et al in 1997(197). They demonstrated CD8+ CTL activity was detectable 
at 3 days p.i. and reached peak level at 10 days p.i. in chickens inoculated with IBV of the 
nephropathogenic Gray strain. The CD8+ CTL activity appeared and reached the peak prior to the 
response of IgM (detectable at 10 days p.i. and peaked at 12 days p.i.) and IgY (minimal level at 
15 days p.i. and peaked at 30 days p.i.). The CTL responses were demonstrated to directly correlate 
with initial decreases in IBV infection and illness(197). Seo et al further demonstrated adaptive 
transfer of antigen-specific CD8+ αβ T cells protected naïve chickens from IBV infection(202). 
Local immunity mediated by CTL in trachea mucosa was also shown to be involved in clearance 
of IBV virus at the mucosal site, evident by significant increases in the number of CTL at 3 days 
p.i. and peaked at 5 days p.i. in infected chicken tracheas(203). Later studies conducted by Pei et 
al demonstrated memory T cells protected chickens from acute infection of IBV(204). Several T 
cell epitopes have been identified from S1 and N proteins of IBV virus that were reported to induce 
CTL responses(161, 205, 206).  With the advance in DNA sequencing technology, transcriptomic 
analysis is a powerful tool that is able to pinpoint the global change of gene expressions involved 
in cellular immune responses against IBV acute infection. Wang et al profiled the transcriptome of 
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immune responses during early infection of IBV in chickens, revealed that significantly elevated 
gene expressions involved in CTL activity include granzyme A precursor, Fas, CD3 gamma delta 
chain, TLR-2, and MHC II. CTL mediated response could target a broader spectrum of IBV strains 
than does antibody response, which is not able to target heterotypic viruses. Understanding CTL 
mediated immunity against IBV is beneficial to the prophylactic development of a universal 
vaccine. More conserved T cell epitopes needed to be characterized in future.  
1.4 Current Vaccines fall short to control AI and IB 
1.4.1 AI vaccines 
Vaccination has emerged as a principal strategy to stop the spread of AI in poultry. To stop 
HPAI, a vaccine was first implemented in Mexico and Pakistan in 1995. The most successful 
example is the compulsory vaccination program to combat HPAI H5N via vaccination of all raised 
and sold poultry in 2002 in Hong Kong Special Administrative Region of China. No further 
outbreak of H5N1 has been identified since 2003 after the initiation of the program(207, 208). 
There are currently five major types of AI licensed or experimental vaccines including inactivated, 
live, recombinant vector, DNA vaccines and subunit.  
Inactivated AI vaccines are the predominant commercial-licensed vaccines available in 
market for use in poultry. They are made from LPAI strains or occasionally from HPAI strains 
from an outbreak, following chemical inactivation with formalin, β-propiolactone, or 
ethyleneimine(208, 209). All formulations of AI inactivated vaccines were prepared in oil emulsion 
adjuvant of either ‘water-in-oil (W/O)’ or ‘water-in-oil-water (W/O/W’) (208), for which 
mechanisms of action include creating a depot microenvironment for the gradually release of 
immunogen, protecting enzymatic degradation, and increasing interaction between surfactant and 
lipid membrane of antigen presenting cells to favor antigen uptake(210). Production of antibody is 
the predominant response induced by AI whole inactivated vaccines(211-213). AI whole 
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inactivated vaccines have been demonstrated to be effective in protection of poultry against AI(213-
215). Billions of doses of AI whole inactivated vaccines have been widely implemented in different 
geological regions around the world in control and eradication programs for AIVs, including usages 
in Minnesota against seasonal LPAI (1996), Northern Italy against H7N1 and H7N3 (2000-2006), 
Middle East and Asia against H9N2 (late 1990-present), and South America-Mexico, Guatemala 
and El Salvador (1995–2006) against H5N2. The inactivated H5N2 was also extensively used to 
control HPAI H5N1 in China (2004), India (2006), Pakistan (2006), Vietnam (2005), Russia (2005) 
and Egypt (2006) (209). Although AI whole inactivated vaccines have attractive potency against 
homologous AI strains in field, there are several disadvantages that limit their practical application 
because they require parenteral administration. However, handling individual bird is very 
laborious. It takes almost a year to reformulate an effective AI whole inactivated vaccine. The 
limited window of time means it may not be in time in response to emergence of HPAI outbreak. 
It’s difficult to differentiate infected from vaccinated animals(216).  
In contrast to AI inactivated vaccines, live AI vaccines made from live LPAI strains or 
virulent-attenuated HPAI strains have superior potency in protection. As live vaccine can mimic 
natural infections in the host, viral antigens are able to presented by both MHC I and P pathway. 
So, they activate robust humoral, mucosal and cytotoxic cellular immune responses. They have 
shown uncompetitive efficacy in poultry as well as in mammals(217, 218). FluMist is the well-
known trademark of a cold-adapted live attenuated vaccine for use in humans(219). In addition, 
another advantage is that live AI could be mass applied in poultry via spray or drinking water(220). 
However, live AI vaccines, especially vaccines against H5 and H7 subtypes, are not recommended 
in poultry since they might reverse to HPAIV via reassortment with field viruses(221). Besides, it 
causes respiratory disease when it is applied in poultry, which make it difficult to differentiate 
natural infection from vaccination in birds. 
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With the advance of DNA recombinant technology, DNA vaccines have emerged as a tool 
to design vaccines against AI. AIV genes encoded in the plasmid vector under a eukaryotic 
promoter can be actively transcribed in vivo and translated into proteins, and therefore is able to 
stimulate MHC I pathway for the induction of cytotoxic T cell responses(222). Although promising 
results of DNA vaccines have been obtained(223-225), no DNA vaccine against AI is licensed. Its 
limitation for application is due to its cost and scale of production as well as labor requirements of 
intramuscular vaccination(226).  
Recombinant vector vaccine is another type of current vaccine taking advantage of DNA 
recombinant technology. HA epitopes expressed in virus or bacteria vectors are not only able to 
trigger robust humoral and cellular immunity but also address the safety concerns of mutations in 
live AI vaccines. The vaccines can be administered by spray without catching and handling birds. 
HA of H5 or H7 expressed in several forms of recombinant vectors have been studied, including 
adenovirus(227), vaccinia (228), Newcastle disease virus (NDV) (229, 230), fowlpox virus (FPV) 
(231-234), turkey herpes virus virus (HVT) (235), duck enteritis virus (DEV) (236) and infectious 
laryntracheitis virus (ILTV) (237). FPV vaccine is investigated most extensively. H5-FPV (2006) 
and H5-NDV (2008) vaccines have been commercially licensed and used in the field in China. 
More than 10 billion doses of these vaccines have been used in China(238).  
Subunit vaccines for AI contain non-replicating proteins without the concern of safety. 
AIV viral proteins HA, NA and M2e have been expressed in many forms such as plant cells, insect 
cells, bacteria and viruses. Shoji et al demonstrated plant derived HA of H5N1 provided protection 
against challenge of HPAIV H5N1 A/Indonesia/05/05 strain in ferrets(239). HA genes of H5 and 
H7 expressed by insect baculovirus protected chickens from lethal challenge with H5 and H7 
subtypes(240).  FluBlok, a currently licensed trivalent vaccine in the U.S, is also expressed in insect 
cells using baculovirus expression system(241, 242). Subunit vaccines are less potent than whole 
virus vaccines, requiring adjuvant in the formulation. To improve the immunogenicity of subunit 
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AI vaccine, several delivery systems have emerged, including virus like particles(243, 244) and 
nanoparticle delivery platform(245, 246).   
1.4.2 IB vaccines 
Current licensed vaccines against IB are live attenuated and killed vaccine. Live attenuated 
vaccine is the first generation of IB vaccine, which could be administered in ovo before hatching, 
via driving water or by spraying within one-week age(147). IB live vaccine could be administered 
alone or with the combination of other live virus vaccines such as NDV, Marek’s disease virus 
(MDV) and infectious bursa disease virus (IBDV) (247). IB live vaccines are geographically 
region-specific. Different variants of IBV strains have been selected to produce live IB vaccines 
under the guideline of epidemiological data regarding the prevalence of IBV in a given area. 
Despite the superior potency of live attenuated IB vaccines in activation of humoral and cellular 
immune responses against local IBV strain, they contribute to a lot of issues during their extensive 
application in field practice. IBV is a rapidly evolved coronavirus. Zhao et al demonstrated IBV 
evolved at approximately 10− 5 substitutions per site per year, giving rise to a unique QX strain with 
increasing proportion over the past twenty years(248). Live viral vaccines have emerged to reverse 
to virulent strains via mutation(249, 250). Following live vaccination, virus subpopulations with 
more fitness and mutations associated with replication of IB live vaccines have been selected(251). 
It has been demonstrated that new variants can be derived from recombination among different 
strains during replication in the infected host cells(252). Emergent new variants derived from 
recombination between live vaccine strains and field strains have been observed around the 
world(253-255). Moreover, the application of live attenuated vaccines against IB is limited by the 
inference of maternal antibodies(256). Importantly, evidence has shown live IB vaccines cause 
respiratory diseases giving opportunity for secondary infections with E. coli, colibacillosis and 
Mycoplasma (257, 258). To balance the safety concern of live IB vaccines, killed vaccines have 
been developed and licensed for commercial use. Killed IB vaccines primarily induce a humoral 
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response. Killed IB vaccines are poorly immunogenic, which require priming with live vaccine and 
oil-emulsion adjuvant. They are typically applied in layers and breeders for boosting 
immunization(184, 259, 260).  
In addition to current licensed IB vaccines, a variety of vaccine technologies have emerged 
to abrogate the safety issue of live vaccines and poor immunogenicity of killed vaccines against 
IB, including viral vector vaccine, subunit peptide vaccine, DNA vaccine and reverse genetic 
vaccine. It has been shown FPV vector expressing S1 gene of IBV alone or co-expressing with 
IFNγ conferred significant protection against IBV challenge(261, 262). Despite poor 
immunogenicity, subunit vaccines are incredibly safe. To overcome this, the virus-like particle 
(VLP) strategy has been proven to improve immunogenicity of IB subunit vaccines. Spike protein 
and M proteins presented in VLPs have shown promising improvements in immunogenicity(263, 
264).  DNA vaccines are able to overcome the issues of inadequate induction of cytotoxic T cell 
response. Several experimental vaccines against IB based on recombinant DNA have shown 
promising results. Tang et al demonstrated a plasmid co-expressing IBV nucleoprotein and 
interleukin-2 induced elevated percentage of CD3+, CD3+CD8+ and CD3+CD4+ subgroups of 
peripheral blood T-lymphocytes, providing protection from virulent challenge(265). DNA vaccine 
is also applied in prime-boost vaccination strategy to enhance immunogenicity of IB vaccine(205). 
Reverse genetic technology is believed to overcome the interference of pre-existing immunity 
against live virus vaccines and viral vector based vaccines. It has been intensively used to substitute 
a virulent gene with a corresponding gene from nonvirulent IBV strains. It has demonstrated 
promising protection in chickens against IB(266-269). Although those alternative vaccines showed 
great promise in a laboratory setting, they have yet to be licensed due to other similar issues that 
were discussed in previous section. It’s necessary to develop a more innovative vaccine platform.   
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1.5 Self-assembling protein-based nanoparticle vaccines: potential alternatives  
Vaccines are one of the most outstanding innovations in the area of public health. It saves 
millions of lives via the prevention of infectious diseases. It has been two centuries since the 
English physician Edward Jenner, “the father of immunology”, devised the terms- vaccine and 
vaccination, and initiated the first protective vaccine against smallpox using live cowpox virus in 
1798. Many effective vaccines have been developed in the past two hundred years. The majority 
of them were produced using traditional methods of attenuating live pathogens or chemically 
inactivating the whole pathogenic organisms. Live attenuated vaccines are highly protective but 
bear inherent safety concerns of reactivation of virulent state. In contrast, chemically inactivated 
vaccines cannot regain the virulent state of derivative pathogens and are safer. However, they are 
poorly immunogenic inducing weaker protection. The breakthrough progress of genetic 
engineering in the 1980s allowed vaccinologists with safety concerns to develop subunit vaccines, 
which contain one or multiple antigens from a whole pathogen. The surface antigen of hepatitis B 
(HBsAg) was the first antigen synthesized and assembled into particles in yeast using recombinant 
DNA technology, which have properties similar to 22 nm virus-like particles (VLP) secreted by 
infected human cells(270). The newly genetically altered vaccine against Hepatitis B was licensed 
in 1986(271). The vaccine against Hepatitis B is also considered as the first successful use of a 
nanoparticle (NP) in vaccination. Since then, the concept of nanoparticle vaccine or nano scale 
vaccine has been expanded to the design of immunogens using a wide range of carrier materials at 
nano scale ranging from 1-1000nm, which include VLPs, virosomes, liposome, emulsion, polymer-
copolymer NP, viral vector, immune-stimulating complex (ISCOM) and self-assembled protein NP 
(272). NP vaccines are safe due to their non-replicating nature. They can be easily engulfed by 
antigen presenting cells because of their well-defined controllable shape and size that resemble a 
virus particle(273, 274).  NP is typically constructed with a repetitive building scaffold, making NP 
vaccines with repetitive surfaces of antigenic epitopes. This constitutes multivalence, which is able 
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to cross-link B cell receptors and activate maturation of naïve B cells(275). In addition, NP vaccines 
have also demonstrated induction of memory cytotoxic T cell responses against malaria via cross-
presentation, which was associated with antigen-associated protein in early endosomes(276). Most 
importantly, NP vaccines have demonstrated self-adjuvanted or compositional controllability of 
co-displaying immunostimulatory molecules(246, 277). Therefore, the use of NP vaccines offers 
an excellent solution to the long-standing issue of safety versus immunogenicity.  
Among different categories of NP vaccines, self-assembling protein nanoparticles (SAPN), 
based on coiled-coil folding domains, have emerged as one of most appealing tools in vaccine 
design. The α-helical coiled-coils are highly versatile protein oligomerization domains 
characterized by seven-residue repeats called heptad repeats. Apolar residues preferentially occur 
in the first (a) or fourth (d) positions within a heptad repeat while the fifth (e) or seventh (g) 
positions prefer charged residues. A linear peptide chain containing heptad repeats is able to fold 
into a left-handed α-helix driven by intramolecularly hydrophobic interaction between ‘a’ and ‘d’ 
apolar residues. The α-helix is stabilized by intramolecular ionic interaction between ‘e’ and ‘g’ 
charged residues. Coiled-coils consist of two to five α-helices and can self-assemble into supercoils 
via intermolecular ‘knobs-into-holes’ interaction forming a hydrophobic core, in which the 
quaternary structure of supercoils is stabilized by intermolecular ionic interactions between side 
chains of charged residues(278-280). This is the principle of oligomerization of coiled-coil 
domains. Raman et al first presented the idea of using coiled-coil oligomerization domains to 
produce nanoparticles. They demonstrated chimeric peptides consisting of two coiled coils 
connected by a short linker region that are capable of self-assembly into a roughly spherical 
nanoparticle with regular symmetry. It was reported that 60 monomeric peptide chains containing 
two chimeric coiled-coil domains of two or three and five α-helices were able to self-assemble into 
nanoparticles with dodecahedron/icosahedron symmetry. The resultant nanoparticles had a size 
range from 16nm to 25nm, which resembled virus capsids(281).  This platform was demonstrated 
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to be a well-suited vaccine delivery system against infectious disease. B cell epitopes could be 
linked to two both ends of chimeric coiled-coil folding domains in a monomeric peptide chain. NP 
resulting from self-assembly of these monomers allows the repetitive presentation of oligomeric 
antigens on the NP surfaces in their native conformations, by which the oligomerization state of 
the epitopes is determined by the oligomerization state of their adjacent coiled-coils(282). The 
Burkhard group developed this well-understood toolbox to successfully generate prototypic 
vaccines against SARS, HIV, and Malaria. In the study of prototypic SAPN vaccine against SARS, 
they demonstrated mice immunized with SAPN displaying coiled-coil epitope from the spike 
protein of SARS virus elicited conformation-specific neutralizing antibodies recognizing the α-
helical heptad repeat region at the C terminus of the Spike protein(283). SAPN was also used for 
conformation-specific display 4E10 and 2F5 epitopes of HIV(284). A T helper cell epitope 
(PADRE) engineered into the trimerization domain made the resultant SAPN self-adjuvanted in 
malaria prototypic vaccine design. Robust, long lasting humoral and cellular immune responses 
against malaria were induced by B and cytotoxic T cell epitopes joined to both ends of 
pentamerization and trimerization domains respectively (277, 285). These successful applications 
of SAPN in vaccine design further demonstrate that SAPN could be potential alternatives to current 
live and killed vaccines against avian influenza and infectious bronchitis, providing outstanding 
safety versus enhancing immunogenicity of the vaccines.  
1.6 Rationale and central hypothesis of the proposed studies 
1.6.1 Rationale 
The rationale of the use of SAPN. SAPN with self-adjuvanted property is proposed to be 
an alternative to traditional vaccines--live attenuated or killed vaccines for the two model diseases 
of avian influenza and infectious bronchitis. SAPN has a number of advantages such as flexible 
		 35 
amendment of epitope inclusion, safety, self-adjuvanted, allowing repetitive antigen presentation, 
and allowing easy incorporation of immunopotentiators for self-adjuvanted property.  
         To maximize the immunopotential, the concept of self-adjuvanting is introduced to the SAPN 
formulation by adding immunopotentiators. Major histocompatibility complex (MHC) molecules 
are essential in host-pathogen recognition and determine the onset and outcome of host immune 
responses(115). MHC molecules have a high degree of polymorphism in population, which is one 
mechanism for fighting against varieties of pathogens(286). According to this rationale, we 
introduce the oligomerization domain- the tetrameric coiled-coils of all our SAPNs a characterized 
well-known pan-allelic DR-binding sequence (PADRE) (AQFVRALSMQAAE), which 
universally activates T helper cells. Hence, PADRE sequences are included in core scaffolds of all 
our SAPNs so that the resultant SAPN pan-activate T helper cells regardless of chicken haplotypes. 
Previous studies on malaria-SAPN had demonstrated the role of PADRE contributing to the self-
adjuvanted property of SAPN(277). 
Flagellin is known to stimulate TLR5 on the surface of APC cells leading to recruitment 
and activation of immune cells as well as cytokine secretion, which contribute to the further 
engagement of antigen or immunogen presentation.  Self-adjuvanted SAPNs can be prepared by 
co-assembly of two protein chains – a small percentage of one with a flagellin fragment replacing 
one of the B cell epitopes and one with both B cell epitopes - into one single SAPN (Figure 1.6 E 
and Figure 1.7). By displaying antigens multiple times as well as displaying flagellin, our self-
adjuvanted SAPNs mimic a whole organism vaccine leading to increased immunogenicity, while 
maintaining the increased specificity, safety, and decreased cost of subunit vaccines without the 
use of commercial adjuvants.  
.  M2e is a small AIV transmembrane protein with a native tetrameric structure, playing an 
essential role in influenza viral infection functioning as a pH-dependent proton channel(54). It has 
been reported as a highly conserved antigen in both human and avian influenza A viruses 
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independent of variant subtypes, making a great target for the design of a universal vaccine against 
AIV(287). The monomeric form of M2e is not immunogenic but the tetramer of M2e is(288). 
Therefore, M2e will be expressed at the N terminus of all monomeric building peptides for all 
versions of our SAPNs (Figure 1.6 A, B, C and D). Inducing neutralizing antibodies against AIVs 
is a gold standard for conferring protection from their infection. Hemagglutinin (HA), a surface 
spike protein that interacts with sialic acid receptors on host cells for virus entry, is a primary target 
of neutralizing antibodies(289). Production of AIV neutralizing antibodies is dependent on HA 
antigens’ conformation-specific presentation to the immune system. Rapid and continuous 
mutations in HA challenge efforts in designing influenza vaccines targeting induction of 
neutralizing antibodies. However, stalk regions of HA have been revealed as conserved regions for 
the induction of broad neutralizing antibodies(290). It was reported that a broad neutralizing 
antibody, CR6261, recognized a highly conserved helical region in the membrane-proximal stem 
of HA, neutralizing H1, H2, H5, H6, H8 and H9 subtypes (289). This indicates the value of eliciting 
CR6261-like antibodies as a practical strategy in vaccine design to prevent influenza. Crystal 
structure of the stalk helix region of HA revealed that long C-Helixes and short A Helix in the form 
of trimeric coiled-coil structure are packed against the helix bundle, conferring the machinery of 
membrane fusion during infection. These trimeric coiled-coil helixes are highly conserved and 
recognized by CR6261 antibody(289). Therefore, HA363-383 and HA416-448 from the highly 
pathogenic strain A/chicken/1/1983 (H5N2) are trimeric coiled-coil A and C Helices, which should 
be optimal B cell epitopes to construct our M2e/Hel A SAPN and M2e/Hel C SAPNs, respectively 
(Figure 1.6 B and D, Helix A and Helix C highlighted in gold color). We hypothesized they would 
induce CR6261-like antibodies against AIV. Organization of epitopes on the nanocarrier is shown 
in Figure 1.7.  
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Figure 1. 4  Amino acid sequence of each SAPN monomer.  
 Each monomer consists of M2e followed by a tetrameric oligomerization domain, linker, trimeric 
oligomerization domain, and HA stalk antigen. Color scheme teal: tetrameric coiled-coil domain, 
blue: trimeric coiled-coil domain, pink: CD4+ epitope, red: M2e B-Cell antigen, gold: HA stalk B-
Cell antigen, black linker sequence, and purple: TLR5 agonist flagellin. 
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Figure 1. 5 Organization of epitopes in SAPN vaccine.  
The rationale of the chosen epitopes of IBV. The S protein of IBV is responsible for 
receptor-biding activity containing epitopes of virus-neutralization and hemagglutination 
inhibition(152). In addition, IBV’s S glycosylated protein contains two coiled-coil sequences as in 
the S protein of SARS. The second sequence (HR2) (residues 1056-1083: 
ILDIDSEIDRIQGVIQGLNDSLIDLEKL) is homologous to the HRC sequence of S protein in 
SARS (HRC, residues 1158-1185: VVNIQKEIDRLNEVAKNL NESLIDLQEL), which has been 
demonstrated to be capable of inducing neutralizing antibodies against SARS infection in vitro. 
Hence, this coiled-coil HR 2 will be selected as a B cell epitope (Figure 1.6 A and B). Amino acids 
of peptide monomers are showed in Figure 1.7. We construct two constructs of SAPN for IBV, 
namely IBV-Flagellin SAPN (co-assembling peptides showed in Figure 1.9 A and B at molar ratio 
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58: 2) and Flagellin SAPN (co-assembling peptides showed in Figure 1.9 B, that are devoid of IBV 
epitope serving as a negative control)  
 
 
 
Figure 1. 6 Coronavirus S protein. A: domains within S proteins of IBV and SARS.  
FP: fusion peptide; HR1: first heptad repeat sequence; IHD: inter-heptad repeat domain; TM: 
transmembrane domain; RBD: receptor binding domain; Cyto: cytoplasmic domain. B: comparing 
the second coiled coil sequences (HR2) of S proteins of IBV and SARS. Letter ‘a’ and ‘d’ denotes 
the first and the fourth hydrophobic amino acids of heptad repeat sequences.  
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Figure 1. 7 Peptide sequences of monomeric building blocks of SAPN for IBV.  
Monomers A & B will be co-assembled at molar ratio of 58: 2 to refold into ‘IBV-Flagellin SAPN’; 
Monomer B will be used to assemble into a SAPN devoid of IBV eptitope-Flagellin- SAPN’ that 
will serve as negative control. Color scheme: Red, malaria B cell epitope (A); Gold： S1 B cell 
epitopes; Green: pantameric coiled-coil; Teal: trimeric coiled-coil; Blue: HR2 B cell epitope; 
Black: linker sequence; Pink: CD4 T cell epitope (AKFVAAWTLKAAA; 
HAAHAAHAAHAAHAA); Purple: The sequence of flagellin D1 and D2 domains. 
1.6.2 Central hypothesis 
Self-assembled peptide nanoparticle formulations are able to preserve and present 
conformational conserved epitopes and further protect chickens from infections with viral 
respiratory pathogens AIV or IBV.  
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Chapter 2 Evaluation of immunogenicity of vaccine prototype for avian 
influenza virus 
Abstract 
Current avian influenza (AI) vaccines should be improved by the addition of 
universal influenza vaccine antigens in order to protect against multiple virus strains. We 
used our self-assembling protein nanoparticles (SAPNs) to display the two conserved 
influenza antigens M2e and Helix C in their native oligomerization states. To further 
improve the immunogenicity of the SAPNs, we designed and incorporated the TLR5 
agonist flagellin into the SAPNs to generate self-adjuvanted SAPNs. We demonstrate that 
addition of flagellin does not affect the ability of SAPNs to self-assemble and that they are 
able to stimulate TLR5 in a dose-dependent manner. Chickens vaccinated with the self-
adjuvanted SAPNs induce significantly higher levels of antibodies than those with 
unadjuvanted SAPNs and show higher cross-neutralizing activity compared to a 
commercial inactivated virus vaccine. Thus, we have generated a self-adjuvanted SAPN 
with a great potential as a universal vaccine for AI. 
2.1 Introduction 
Avian influenza (AI) is an infectious disease in domestic and wild avian species 
caused by avian influenza virus (AIV). Vaccination is the most effective approach to 
control AI(291). Current available vaccines for AI are seasonal vaccines and are generally 
live attenuated or chemically inactivated whole viruses. However, the effectiveness of 
		 42 
these licensed vaccines depends on the correct prediction of virus strains likely to cause 
next epidemics. Inaccurate prediction of the selected vaccine strains will result in a partial 
or complete failure of the vaccine. Protective antibodies induced by seasonal vaccines are 
highly strain-specific as they are mainly directed against variable regions of the 
immunodominant globular head domain of hemagglutinin (HA) or neuraminidase (NA), 
the major surface proteins of the virus.  
In addition to seasonal epidemics, irregularly AI pandemics occur because of AIV 
that have crossed the species barrier, which can cause high levels of mortality in 
humans(24, 25). The limitation caused by antigenic drift, due to mutations in the surface 
proteins (HA and NA), and antigenic shift, due to exchange of surface proteins with 
different ones from other strains, calls for new concepts in influenza vaccine development 
involving conserved epitopes that elicit cross-protective antibodies that target multiple 
pathways in influenza's infection process. An effective universal vaccine on its own or as 
an additional component to complement an existing seasonal vaccine could be used to 
increase vaccine efficasy in case of mismatch of vaccine strains to the circulating strains 
and providing an effective response against future AI pandemics. 
Nanoscale assemblies provide perhaps one of the most adaptive and useful 
approaches in repetitive antigen display, allowing for increased immunogenicity(292, 293). 
One such nanoscale assembly that is very promising for the future of vaccine development 
is the Self-Assembling Protein Nanoparticle (SAPN) (245, 277, 283-285, 294). Each 
SAPN monomer contains two coiled-coil oligomerization domains held together by a 
linker(281). On both the N and C terminus of the monomer, known antigens can be added. 
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SAPN monomers self-assemble into small particles about the size of a small virus and can 
be displayed on their surface with antigens.  
Since subunit vaccines tend to be less immunogenic than whole organism 
vaccines(292), suitable adjuvant formulation is an important consideration. A good 
adjuvant formulation includes a delivery system and an immunopotentiator(295). A new 
approach that we can take is the addition of an immunostimulatory molecule to the SAPN 
to generate a self-adjuvanted SAPN, as we call them. One such class of immunostimulatory 
molecules is pathogen-associated molecular patterns (PAMPs). These molecules are 
known to stimulate both the innate and adaptive immune system upon exposure to an 
invading microorganism. One of the best-characterized PAMPs with established adjuvant 
function is flagellin, present on flagellated bacteria(296, 297). Flagellin stimulates Toll-
Like Receptor 5 (TLR5) on the surface of cells in both the innate and adaptive immune 
system, leading to recruitment and activation of immune cells as well as cytokine 
secretion(296-301). Self-adjuvanted SAPNs can be prepared by co-assembly of two 
protein chains. This will lead to increased immunogenicity, while maintaining the 
increased specificity, safety, and decreased cost of subunit vaccines.  
We have applied the new self-adjuvanted SAPN technology to the development of 
a universal influenza vaccine. With the intent of designing a universal vaccine that will 
have broad protective capacity, we have incorporated two known conserved antigens to be 
presented on our SAPNs. The first was the ectodomain of the matrix protein 2 (M2e), which 
has previously been added to a SAPN(245) and results in specific antibody production and 
a reduction in viral shedding from vaccinated hosts due to an ADCC type of immune 
response. Since M2e is a tetramer, we used a special type of octahedral SAPN that is 
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composed of tetrameric and trimeric coiled-coil domains and attached the M2e domain to 
the tetrameric coiled-coil. To further optimize this design, we have now added a conserved 
immunogenic region from the Helix C of the hemagglutinin stalk domain that was 
previously shown to elicit virus-neutralizing antibodies(302). Since Helix C is a trimeric 
coiled-coil, we have added this epitope to the trimer domain of the octahedral SAPN. 
We generated two vaccine prototypes: MC-Penn and SA-MC-Penn. We used the 
M2e and Helix C sequences from the high pathogenic strain 
A/chicken/Pennsylvania/1/1983 (H5N2). Based on successful initial stability and 
immunogenicity studies of MC-Penn, co-assembly with flagellin-containing protein chains 
was performed to generate self-adjuvanted SAPNs (SA-MC-Penn). Incorporation of 
flagellin did not affect self-assembly into small regular spherical particles and the SAPNs 
were able to stimulate TLR5 in vitro, indicating that flagellin was correctly presented and 
should function as an adjuvant in vivo. Chickens immunized with SA-MC-Penn generated 
significantly higher titers of neutralizing antibodies in comparison to those vaccinated with 
unadjuvanted MC-Penn. Antibodies from animals vaccinated with the SA-MC-Penn 
showed not only a high degree of cross-neutralization activity within group 1 influenza 
strains in vitro, but also cross-neutralization to group 2 influenza strains better than a 
commercial inactivated virus vaccine.  
Together, these data indicate that we have successfully designed a new self-
adjuvanted SAPN as an effective universal influenza vaccine or vaccine component. 
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2.2 Materials and Methods 
2.2.1 Cell Lines and Viruses 
 TLR5 SeaPorter cell line (Novus Biologicals, Littleton, CO) was maintained as per 
manufacturer’s instructions. Madin-Darby Canine Kidney (MDCK) cells were cultured in the 
MEM medium (GIBCO) supplemented with 4 mM L-Glutamine (GIBCO) and 10% fetal bovine 
serum (FBS) (HyClone) in a humidified incubator with 5% CO2 at 37 °C. Low pathogenic H5N2 
virus (A/Turkey/CA/D0208651-C/02), H1N1 (A/Swine/WSN/1933), H5N3 
(A/Turkey/CA/21860/84), H5N9 (A/Turkey/WI/1968), H6N8 (A/Turkey/Canada/63), H7N2 
(A/Chicken/NY/2003), and H10N7 (A/Turkey/MN/19/1979) were propagated in 9-day old 
embryonating Specific Pathogen Free (SPF) chicken eggs (Charles River) for 3 days. 
2.2.2 Gene Synthesis 
 A gene containing the SAPN core along with M2e (residues 2-23) on the 5’ end and Helix 
C (residues 165-197) on the 3’ end from H5N2 (A/Chicken/Pennsylvania/1/1983) followed by a 
6x HisTag was designed (Supp. Fig 1A, C). This gene and a second gene containing the D0 and 
D1 domains (residues 1-177 and 249-372 connected with a short linker, KYKDGKGDDK) of 
flagellin from Salmonella enterica serovar Typhimurium (Supp. Fig 1B, D) were synthesized by 
GeneScript USA Inc (Piscatway, NJ). The flagellin sequence was cloned into the gene containing 
M2e and the SAPN core replacing the Helix C sequence resulting in a gene for the avian and the 
human vaccine. 
2.2.3 Protein Expression 
 Protein expression for both constructs was carried out at 37ºC in 1 L of Luria broth 
containing 200m g/mL ampicillin and 30m g/mL chloramphenicol. Induction with 1 mM isopropyl 
b-D-thiogalactopyranoside occurred when the culture reached an OD600 of 0.8. After 4 hours of 
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induction cells were harvested by centrifugation at 4,000x g at 4ºC for 15 minutes and stored at -
80ºC.  
2.2.4 Protein Purification 
 Cell pellets were thawed on ice and resuspended in imidazole free buffer (8M urea, 100 
mM NaH2PO4, 20mM Tris base, pH 8.0), lysed by sonication, and centrifuged at 30,500 x g for 25 
minutes to clarify the lysate. Purification was carried out on a ÄKTApurifier 100 (GE Healthcare, 
Piscataway, NJ) using a 5 mL HisTrap HP column (GE Healthcare, Piscataway, NJ) under 
denaturing conditions. Protein was eluted using a 500mM imidazole gradient. The resulting 
recovered protein was verified by a SDS-Page, and dialyzed overnight into prerefolding buffer (8 
M Urea, 50 mM NaCl, 20 mM Tris, 5% Glycerol pH 8.0).  
2.2.5 Co-assembly and SAPN Refolding 
The concentration of each construct was determined using a NanoDrop 2000 (Thermo 
Scientific, Wilmington, DE). Based upon the concentration a molar ratio was established that 
contained either a ratio of 58:2 (avian flu) or 55:5 (human flu) M2e/Helix C monomers to flagellin 
monomers. All samples were dialyzed in a stepwise manner into the refolding buffer (20 mM Tris 
base, 5% glycerol, pH 8.5) slowly removing the urea to allow for efficient refolding.  
2.2.6 Dynamic Light Scattering 
SAPN formation was monitored by determining the hydrodynamic diameter at 25ºC using 
a Malvern Zetasizer Nano S (Malvern, Worcestershire, UK) equipped with a 633-nm laser. Each 
sample was run 5 times, and the average result taken.  
2.2.7 Transmission Electron Microscopy  
Samples were adsorbed onto carbon-coated grids (Electron Microscopy Sciences Inc., 
Hatfield, PA) and negatively stained with 0.5% to 2% uranyl acetate (Electron Microscopy 
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Sciences Inc., Hatfield, PA). Electron micrographs were taken on an FEI Tecnai T12 Transmission 
Electron Microscope.   
2.2.8 In vitro TLR5 Response Assay  
TLR5 SeaPorter cells at passages 5-9 were seeded 14,000 cells per well in a 96 well plate. 
After 24 hours, growth media was removed and replaced with DMEM High glucose (Hyclone, 
Logan, UT) containing either one of the three SAPNs, or recombinant flagellin (Novus Biologicals, 
Littleton, CO) in triplicate. Control wells were exposed to media only. After 24 hours of exposure 
supernatant was harvested and used to assay for the presence of secreted alkaline phosphatase using 
Secreted Alkaline Phosphatase Reporter Assay Kit (Novus Biologicals, Littleton, CO) as per 
manufacturer’s instructions. Resulting SEAP activity was normalized to media only controls and 
used to determine the EC50 (effective concentration at 50%) for each construct. The experiment 
was repeated in triplicate.   
2.2.9 Animals and Immunization  
Four weeks of age SPF P2a (B19/B19) white Leghorn chickens were given intramuscularly 
200 µL vaccine containing either 100 µg SAPN, Refolding Buffer, or inactivated H5N3 commercial 
vaccine (Fort Dodge, Fort Dodge, IA) as per manufacturer’s instructions. Each animal received two 
boosters two weeks apart. Chickens were bled once before vaccination and bled 3 times at 2 weeks 
after each immunization. Sera were stored at -80º C until tested. Handling of chickens was under 
guideline of Institutional Animal Care and Use Committee of University of Connecticut, Storrs, 
CT, USA.  
2.2.10 Agglutination of chicken red blood cells 
MC-Penn SAPN was 2-fold serially diluted starting at a concentration of 18µg/mL in PBS. 
Diluted MC-Penn SAPN was incubated with 0.5% chicken red blood cells for 1 hour. 64 HA units 
of HA of H5N2 was used as a positive control and two-fold serially diluted in PBS. H5N2 virus 
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was incubated with 0.5% chicken red blood cells for 1 hour. For a negative control, serial dilution 
of nicotine-SAPN devoid of flu antigens and was incubated with 0.5% chicken red blood cells for 
1 hour. The inhibition of agglutination of chicken red blood cells by MC-Penn SAPN was 
performed using serially diluted anti-sera induced by MC-Penn SAPN. Two-fold serially diluted 
antisera were mixed with 18µg/mL MC-Penn SAPN. The SAPN-sera mixture was incubated with 
0.5% chicken red blood cells for 1 hour. Agglutination was observed and calculated with reciprocal 
checkboard dilution.   
2.2.11 Enzyme-linked Immunosorbent Assay (ELISA) 
ELISA plates (Thermo Scientific) were coated with 50 µL/well of 1 µg/mL peptide antigen 
in carbonate-bicarbonate buffer overnight at 4 °C. Plates were blocked with 100 µL of 3% BSA in 
PBST solution (PBS plus 0.05% Tween 20). Serially-diluted sera starting at 1/100 in 50 µL were 
incubatedin the plates at room temperature for 1 hour. Mouse anti-chicken Ig Y in 50 µL followed 
and incubated in the plates at a 1/1000 dilution at room temperature for 1 hour. 50 µL TMB (Thermo 
scientific) was applied to the plates at room temperature for 5-15 minutes until color developed.  
Reactions were stopped with 0.01% HCl. Plates were read for absorbance of optical density at 
450nm. Dilution endpoints were read until absorbance of optical density reaches 0.2 at OD450nm. 
2.2.12 Plaque Reduction Assay to Assess Neutralizing Antibodies Against Different AIV 
Subtypes 
One hundred plaque-forming-units (PFUs) of low pathogenic AIVs (H1N1, H5N2, H5N3, 
H5N9, H6N8, H7N2 and H10N7) were mixed with diluted anti-sera and incubated at 37ºC for 1h. 
Virus-sera mixtures were inoculated onto confluent MDCK cellular monolayer on 61 cm-plates. 
Sera-virus mixture was incubated with MDCK cells at 37ºC with 5% CO2 for 1 hour. Plates were 
washed for 3 times and overlayed with 2X MEM containing 0.8% agarose, 2 µg/mL TPCK-treated 
trypsin (Sigma, USA) and 1X Fungizone. Cells were incubated in a humidified incubator at 5% 
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CO2 at 37ºC for 3 days. Plates were fixed with 10% neutral formalin and stained with 0.01% Crystal 
violet stain to visualize plaques. 
2.2.13 Statistical Analysis  
Multiple comparisons between experimental groups in the induction of neutralizing 
antibodies were made by repeated measures using two-way ANOVA. Bonferroni was done to 
compare the mean value of each group. P<0.05 is considered as statistically significant. All 
statistical analyses were done in GraphPad 5.0 (San Diego, CA).  
2.3 Results 
2.3.1 SAPN Design and Characterization of SAPN 
We have previously described the design of an octahedral SAPN displaying the tetrameric 
epitope M2e(245). Briefly, M2e is present on the N terminus of the SAPN protein chain attached 
to the tetrameric coiled-coil oligomerization domain of tetrabrachion(303), allowing M2e to be 
presented on the surface of the SAPN in its native immunogenic tetrameric conformation. Thus, 
leading to better immune response including decreased viral shedding(245). To increase TH 
responses, we have also added universal T cell epitopes into the cores of our SAPNs(276, 285, 
294). One such example is the de novo designed Pan-DR TH epitope (AQFVRALSMQAAE) 
derived from the sequence of the so-called PADRE epitope (AKFVAAWTLKAAA) (304, 305). 
This epitope string is predicted to strongly bind to the MHC II molecules of a wide variety of mouse 
and human haplotypes, leading to increased TH responses, and ideally increased immunogenic 
response in the host organism.  
We have now also added a second antigen to the C terminus of the construct. The most 
appealing antigen candidate for us is a conserved region of the stalk domain (Helix C) of HA that 
has previously been shown to be protective(302). The stalk domain of the HA is a homotrimer, and 
in particular, Helix C is a trimeric coiled coil, leading us to use the trimeric coiled-coil 
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oligomerization domain of the SAPN to best present the antigen in its native conformation. Our 
SAPNs are a unique design that is hardly possible using any other technologies. Virus-like particles, 
polymer-based nanoparticles, or liposomes are unlikely to present both of these antigens in their 
native conformation. In particular, our octahedral SAPNs offer the possibility to display M2e in its 
native tetrameric form, and at the same time present the Helix C antigen in its native trimeric coiled-
coil conformation, which will ideally create an effective universal influenza vaccine candidate. To 
generate a universal influenza vaccine, we designed and produced the self-adjuvanted SAPNs based 
on the M2e and Helix C antigens using the sequences of the H5N2 virus 
A/Chicken/Pennsylvania/1/1983.  
We generated self-adjuvanted SAPNs by adding the highly conserved D0 and D1 domains 
of flagellin from Salmonella enterica serovar Typhimurium to the C terminus of a second protein 
chain of the SAPN (Figure 2.1). The D1 domain is the region of flagellin that is the most closely 
correlated with signaling through TLR5, which is what is necessary for strong adjuvant 
function(296, 306). Our design removes the D2 and hypervariable D3 domains, instead replacing 
them with a short linker sequence, which will not affect adjuvant function. Both SAPN protein 
chains contain the same nanoparticle core, which will allow for the formation of a molar co-
assembly ratio of both monomers (Figure 2.2). By generating a molar ratio with low levels of the 
flagellin-containing protein chains, we will be able to generate self-adjuvanted SAPNs that contain 
about 3% flagellin per particle. A low percentage of flagellin will not occlude the B cell epitopes 
M2e and Helix C from interaction with the B-cell receptor (See Figure 2.2). 
All purified constructs were refolded by dialyzing the protein in a stepwise manner into 
refolding buffer. Samples were analyzed by SDS-PAGE gel to visualize the presence of the SAPN 
monomers after refolding (Figure 2.3). Dynamic light scattering (DLS) was used to determine the 
hydrodynamic diameter of the resulting particles and whether the diameter fell within the expected 
SAPN size range from the computer model of about 15-20 nm (Figure 2.4 A). Size and shape of 
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the particles were further validated by transmission electron microscopy (TEM) (Figure 2.4 B-D), 
even though the staining procedure using uranyl acetate at rather low pH raised some issues with 
the pH-sensitive stability of the Helix C. The size and shape of the SAPNs did not change upon the 
addition of flagellin to generate the self-adjuvanted SAPNs. Other SAPNs displaying broad range 
of epitopes derived from HA stalk (Helix A, cleavage peptide and a T cell epitope called B19, 
Figure 2.1 A, B, C) did not form stable particles. So, they were not further pursued in this study. 
2.3.2 Agglutination of chicken red blood cells mediated by MC-Penn SAPN 
Hemagglutination is a long-standing feature of an influenza virus, and is mediated by the 
spike protein HA on the surface of virus capsid. Interestingly, we found MC-Penn SAPN loaded 
with AIV antigens M2e and Helix C are able to agglutinate chicken red blood cells at a protein 
concentration of 2.25µg/mL (Figure 2.5 A), which is similar to the hemagglutination by the H5N2 
virus (Figure 2.5 B). Importantly, the antisera collected from the chickens vaccinated with the MC-
Penn SAPN were able to inhibit the agglutination effect (Figure 2.5 D). 18 µg/mL of SAPN devoid 
of the AIV epitopes failed to mediate agglutination of red blood cells. These results indicated MC-
Penn SAPN has a virus-like characteristic of hemagglutination. 
2.3.3 Flagellin loaded SAPN (SA-MC-Penn) is able to stimulate TLR5 signaling in vitro 
Refolded SAPNs were screened for their ability to stimulate TLR5 using the Human TLR5 
NF-κB/SEAP (SEAPorter) Stable Reporter Cell Line (Novus Biologicals). Upon stimulation of 
TLR5, these cells secreted alkaline phosphatase (SEAP) into the media. SEAP levels can be easily 
quantified and correlated with stimulation of TLR5. Results indicate that flagellin is in its native 
conformation as it is able to efficiently stimulate TLR5 on the reporter cell line for SA-MC-Penn. 
Stimulation increased with increasing dose and with concentrations of flagellin containing SAPNs 
or flagellin (Figure 2.6 A). 
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A simple way to compare the efficacy of different drug formulations is to compare the half 
maximal effective concentrations (EC50) (Figure 2.6 B, C). Based on the EC50s obtained from the 
reporter cell line experiments, it appears that the flagellin-only SAPN (i.e. SAPNs that are built 
from the flagellin-containing protein chain only) alone stimulates TLR5 even more efficiently than 
the recombinant flagellin protein with EC50s of 0.5603 ng/mL and 3.619 ng/mL, respectively. A 
higher concentration of our SA-MC-Penn SAPN is needed to stimulateTLR5, as is indicated by an 
increased EC50 of 6.791 ng/mL. This finding is expected because it contains less flagellin than 
either the flagellin-only SAPN or recombinant flagellin. These data demonstrate that we have 
generated a self-adjuvanted influenza SAPN that forms well-formed spherical particles that are able 
to stimulate TLR5 in vitro, indicating that they should have adjuvant function in vivo. 
2.3.4 SA-MC-Penn induced more robust antibody responses than did MC-Penn in chickens 
  Based upon our initial screening, we wanted to determine the dose response of antibody 
production upon immunization with SAPNs. SPF chickens were vaccinated three times with 100 
µg of either SA-MC-Penn or MC-Penn. Antibody levels specific for the SAPN reached their 
maximum level at 2 weeks post first boost in both SAPN-vaccinated animal groups (Figure 2.7 A). 
The addition of flagellin as a self-adjuvant in SA-MC-Penn results in significantly higher antibody 
levels (P < 0.0001) as compared to MC-Penn alone (Figure 2.7 B). 
2.3.5 SA-MC-Penn induced cross-reactive neutralizing antibodies against different subtypes 
of low pathogenic avian influenza virus 
Neutralizing antibodies are thought to be the gold standard in preventing influenza 
infection. Plaque reduction assays were performed to determine if the antibodies produced after 
vaccination were neutralizing or not (Figure 2.8 A). Antibodies to M2e are thought to be not 
neutralizing but to act as antibody-dependent cell-mediated cytotoxicity (ADCC), so the assay will 
specifically screen for antibodies for Helix C(307). Sera harvested from chickens vaccinated with 
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SA-MC-Penn resulted in 95% reduction in infection of MDCK cells by H5N2 
(A/Turkey/CA/D0208651-C/02) compared with only a 42% reduction by antisera of MC-Penn, 
indicating that the addition of flagellin increases the antibody titers; thus, even at a sera dilution of 
1/100, sera from animals vaccinated with the SA-MC-Penn showed a viral neutralization of about 
50% (Figure 2.8B). Anti-sera induced by SA-MC-Penn not only neutralize the homologous subtype 
H5N2 used for vaccine design but also neutralized heterologous subtypes of influenza viral strains, 
including H1N1, H5N1, H5N3, H5N9, H6N8, H7N2 and H10N7 (Figure 2.8C). Sequence 
comparison of Helix C derived from H5N2 (A/chicken/Pennsylvania/1/1983) with Helix C of 
H1N1, H5N1, H5N3, H5N9, H7N2 and H10N7 revealed a high degree in sequence conservation 
within group1 influenza strains (e.g. H1, H2, H5, H6) (Figure 2.9A) and moderate sequence 
conservation within group 2 influenza strains (e.g. H3, H7, H10) (Figure 2.9B). The cross-
neutralization activity, therefore, nicely correlated with the degree of sequence identity to the Helix 
C sequence of our immunogen (Table 2.1). Most importantly, cross-neutralization activity of the 
SAPN vaccine was significantly better than the one obtained from the commercial inactivated virus 
vaccine, in particular for the viral strains with lower sequence homology (Table 2.1). Collectively, 
these data clearly demonstrate that SA-MC-Penn significantly improved SAPN immunogenicity 
and induced not only substantial viral cross-neutralization activity within group1 influenza strains 
but also significant cross-neutralization within group2 influenza strains in vitro. 
2.4 Discussion 
It has traditionally been difficult to develop effective vaccines for AI due to the highly 
mutable nature of the AIV resulting in mismatch issues(308). The usage of live attenuated vaccines 
in poultry is condemned for their long-standing safety concern of the emergence of new AI strains 
of high virulence(208). Subunit vaccines offer a potential alternative to address this safety issue 
because of their non-replicating nature. However, a subunit vaccine is generally less immunogenic 
than a whole pathogen. To address these issues, we formulated a self-adjuvanted vaccine for AI 
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using a SAPN platform. With regard to the mismatch issue, we repetitively display two broadly 
conserved antigen epitopes of AI in their native oligomerization states, the ectodomain of AI matrix 
protein 2 (M2e) as a tetramer and Helix C (Hel C) of AI hemagglutinin as a trimer. The resulting 
construct is named MC-Penn. To enhance the immunogenicity of MC-Penn, three molar percentage 
of flagellin was co-assembled within the SAPN core as a built-in adjuvant. The resultant SAPN is 
called SA-MC-Penn.  
Hemagglutination is a prominent property of an influenza virus. The mechanism of 
hemagglutination by an influenza virus is dictated by the interaction between sialic acid receptor 
of the host and the globular head of an AI HA protein(309). Anti-sera against the globular head 
have an activity of hemagglutination-inhibition (HAI) whereas anti-sera against a HA stem lacks 
this activity(310). Of interest, MC-Penn, presenting M2e and a conserved stalk sequence of HA 
other than any amino acid sequence from the HA head, is able to mediate the agglutination of 
chicken RBCs. Anti-sera against MC-Penn inhibited the agglutination of RBCs mediated by MC-
Penn. Our finding suggested that MC-Penn has some virus-like surface allowing receptor binding. 
The mechanism of agglutination of RBCs by MC-Penn needs to be defined.  
D0 and D1 domains of a flagellin molecule loaded on a SAPN retained the potential of the 
activation of TLR5 signaling in vitro (Figure 2.6 A). The activity of the activation induced by the 
SAPN-oligomerized flagellin was stronger than the free form of recombinant flagellin (Figure 2.6 
B and C). This might be attributed to a higher molar concentration of the SAPN flagellin than free 
form and to the possibility of a stronger receptor cross-linking mediated by the SAPN flagellin than 
the recombinant one. This is in accordance with the observation that the polymerized form of TLR-
7/8a was more potent than the free form in terms of the activity of immune activation(311). 
Addition of flagellin domains has greatly enhanced the immunogenicity of our SAPN vaccine and 
achieved the goal of self-adjuvanted effect. Antibody responses induced by SA-MC-Penn SAPN of 
self-adjuvanted in chickens was significantly enhanced (Figure 2.7 A and B). SA-MC-Penn SAPN 
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induced a two-fold higher level of neutralizing antibodies in chickens than did MC-Penn (Figure 
2.8A). The neutralizing antibodies induced by SA-MC-Penn are not only cross-reactive to group 1 
AIV but also cross-reactive against group 2 AIV. The cross-reactivity is due to the enhanced 
immunogenicity of the HA stalk epitope, which agreed with previous observations of the stem-
binding neutralizing antibodies such as CR6261, F10, CR8020, FI6, and CR9114(289, 312-315). 
The enhancement of the immunogenicity of the SA-MC-Penn SAPN may be attributed to the 
synchronized activation of T helper cells by the CD4 T cell epitopes and the flagellin molecule 
loaded on the SAPN. These results showed SA-MC-Penn is a promising candidate for testing a 
lethal challenge model with a highly pathogenic avian influenza virus.  
2.5 Contributions 
Dr. Peter Burkhard designed all SAPNs. Dr. Christopher Karch produced and physically 
characterized all SAPNs in Dr. Peter Burkhard’s laboratory. Jianping Li performed all in vitro and 
in vivo studies to evaluate the immunogenicity of SAPN vaccine candidates in chicken model. 
 
Figure 2. 1 Model of Self-Adjuvanted Influenza SAPN. 
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 (A) M2e/Helix C-SAPN Monomer. (B) Flagellin-SAPN Monomer. (C) 24 monomers self-
assemble into the SA-MC-SAPN with predicted octahedral symmetry.  Color scheme red: M2e B-
cell antigen, teal: tetrameric coiled-coil domain, blue: trimeric coiled-coil domain, pink: PADRE 
CD4+ epitope, gold: Helix C antigen, black: linker sequence, and purple: TLR5 agonist flagellin. 
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Figure 2. 2 Model of self-adjuvanted influenza SAPN.  
(A) M2e/Helix C-SAPN monomer. (B) Flagellin-SAPN monomer. (C) 24 monomers self-assemble 
into the SA-MC-SAPN with predicted octahedral symmetry. Color scheme red: M2e B-cell 
antigen, teal: tetrameric coiled-coil domain, blue: trimeric coiled-coil domain, pink: PADRE CD4+ 
epitope, gold: Helix C antigen, black: linker sequence, and purple: TLR5 agonist flagellin. 
                                        
Figure 2. 3 SDS-PAGE of refolded SAPN.   
4.5 mg of SAPNs were used in SDS-PAGE analysis. M: ladder; Lane 1: MC-Penn; Lane 2: SA-
MC-Penn; Lane 3: Flagellin SAPN. 
 
Figure 2. 4 Biophysical Characterizations of SAPNs.   
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(A) Each refolded sample was analyzed using DLS to determine that a particle of the predicted size 
had formed. Histogram of size results by volume of MC-Penn, SA-MC-Penn, and MC-Penn-
flagellin. Solid black line MC-Penn, dashed grey line SA-MC-Penn, solid grey line MC-Penn-
flagellin.  (B-D) Electron microscopy of MC-Penn, SA-MC-Penn, and Flagellin-only-SAPN. All 
samples stained with 0.5 to 2% uranyl acetate at a protein concentration of 0.05 to 0.5 mg/mL. 
 
 
 
 
Figure 2. 5 MC-Penn SAPN mediated agglutination and the inhibition of agglutination of 
chicken red blood cells. 
A: MC-Penn SAPN was 2-fold serially diluted starting at concentration of 18µg/mL in PBS. 
Diluted MC-Penn SAPN was incubated with 0.5% chicken red blood cells for 1 hour. B: two-fold 
serially diluted H5N2 virus was incubated with 0.5% chicken red blood cells for 1 hour. C: negative 
control, serial dilution of nicotine-SAPN devoid of flu antigens and was incubated with 0.5% 
chicken red blood cells for 1 hour. D: Inhibition of agglutination of chicken red blood cells was 
performed using serially diluted anti-sera induced by MC-Penn SAPN. Two-fold serially diluted 
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sera were mixed with 18µg/mL MC-Penn SAPN. SAPN-sera mixture was incubated with 0.5% 
chicken red blood cells for 1 hour. 
 
 
 
 
 
 
 
 
Figure 2. 6 In vitro screening of SAPN for TLR5 Stimulation.  
(A) Human TLR5 NF-kB/SEAP (SEAPorter) stable reporter cell line was exposed to varying 
concentrations of MC-Penn, SA-MC-Penn, Flagellin-only-SAPN, and recombinant flagellin. 
Stimulation of TLR5 was measured by the presence of SEAP in the supernatant. Results average 
of three replicates. Error bars are standard error of the means. (B) Nonlinear regression generated 
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by GraphPad of data used to determine the EC50s.  (C) Table comparing the EC50s for SA-MC-
Penn, Flagellin-only-SAPN and recombinant flagellin. 
 
 
 
 
 
 
 
 
Figure 2. 7 Self-Adjuvanted SAPN Induces Significantly Higher Levels of Antibodies.  
Groups of SPF chickens (n=8) were vaccinated with 100µg per chicken of MC-Penn, SA-MC-Penn, 
or unrelated SAPNs at 4-week age. Chickens received 2 boosters of vaccines 2 week apart and bled 
at 2 weeks post vaccination. (A) Antibody titers were determined with sera taken 2 weeks post 
primary vaccination, first boost and second boost. Pooled anti-sera were raised against ELISA plate 
coated with 1 µg /mL MC-Penn. Dilution endpoints were determined when OD450nm reached 0.2 
that OD reading of negative sera intersected with OD reading of tested samples. (B) Sera from each 
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individual chicken at 2weeks post second boost immunization were also diluted at 1/400 and raised 
against ELISA plate that was described previously. One-way ANOVA test was performed to 
compare the antibody response elicited by MC-Penn, SA-MC-Penn and H5 inactivated vaccine 
(*P<0.05, ***P<0.0001).  							
 
Figure 2. 8 SA-MC-Penn Increases Production of Cross-neutralizing Antibodies.  
Antisera collected at time points of 2 weeks post primary vaccination, first boost and second boost 
were pooled and to examine neutralization on H5N2 virus infection in MDCK cells in vitro. 
Percentage of neutralization resulted from sera from vaccinated animals were calculated from % of 
plaque reduction as compared to sera from refolding buffer vaccinated animals. (A). Pooled sera 
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were evaluated at dilution of 1/10 (** p<0.01). (B). Examination of dilution factor on neutralization 
by pooled sera from chickens vaccinated with SA-MC-Penn. (C) Broad cross-neutralization against 
heterozygous subtypes of influenza viruses by pooled sera from chickens vaccinated with SA-MC-
Penn at a dilution of 1/10, represented by un-striped bars in the figure. For the comparison of cross-
neutralization, Sera from chickens immunized with H5N3-inactivated vaccine were also diluted at 
1/10 and applied for plaque reduction, represented by striped bars in the figure.   
 
Figure 2. 9 Sequence Alignment.  
Sequence alignment comparing Helix C of H5N2 (A/chicken/Pennsylvania/1/1983) with group1 
influenza strains (A) or group2 influenza strains (B). * Strains used for neutralization assay by 
plaque reduction assay.  
 
Table 2. 1 Helix C sequence identity and neutralization activity compared to immunogen 
(H5N2-CK-Pennsylvania-1983). 
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Chapter 3 Flagellin built-in protein nanoparticle-based vaccine 
prototype protects chickens from challenge of a highly pathogenic avian 
influenza virus H5N2 
 
ABSTRACT 
We used a platform of self-assembling protein nanoparticles (SAPNs) to develop a self-adjuvanted 
vaccine for avian influenza virus (AIV). A SAPNs named SA-MC-Penn was designed to display 
the ectodomain of influenza matrix protein 2 (M2e) as a tetramer and Helix C (Hel C) of 
hemagglutinin as a trimer. Flagellin domains expressed within a peptide chain were co-assembled 
into the SAPN core serving as a built-in adjuvant. SA-MC-Penn was administered every two weeks 
for three times via the intramuscular (IM) or eye drop (ED) routes in chickens starting at four-
weeks of age. Sera were collected from immunized chickens at twelve-weeks of age prior to 
challenge with a highly pathogenic (HP) H5N2 strain of AIV. ELISA results demonstrated that 
high titers of serum antibodies were induced in the IM immunized SAPNs.  Upon challenge with 
		 64 
HP AIV, 63 % and 30% of chickens the SAPNs IM and SAPN ED groups, respectively, survived. 
A reduction in challenge virus shedding from oropharyngeal swabbings of the SAPNs IM 
vaccinates was observed on days two and 14-post challenge. These results show the SAPNs vaccine 
prototype was partially protective against HP AIV.  
Keywords: Avian Influenza, Nanoparticle, Flagellin, Adjuvant, SAPN, Chicken, Vaccine 
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3.1 Introduction 
Avian influenza (AI) can be a devastating disease of poultry.  Low pathogenic viruses can 
cause little or no observable diease while higly pathogenic (HP) viruses can induce high mortality, 
resulting in massive economic losses for the poultry industry due to loss of birds, trade restrictions 
and disease control and response efforts.  The 2014-2015 US HP outbreak cost producers and the 
US government an estimated 3.3 billion US dollars(316). In previously rare cases, strains may pose 
a public health concern(25).  Outside of the US, vaccination has been shown to be an effective 
measure of controlling AI(317).  However, designing an effective vaccine against AI is challenging 
due to large number of subtypes, the highly mutable genome of the avian influenza virus (AIV), 
and the reassortment of genes among different strains(308).  These issues could easily cause 
mismatch problem between the antigen within the vaccine and circulating field strains, resulting in 
suboptimal vaccine efficacy(318). To solve the problem, one practical strategy is to develop a 
universal vaccine comprised of multiple conserved epitopes against a wide range of AIV 
strains(308, 319).  
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In recent years, designing novel biodegradable nanomaterials with well-defined structures 
that modulate immune responses has attracted substantial attention in vaccine development(320). 
To improve drug delivery, nanosized lipid or polymer-based particle, liposomes, virosomes and 
virus-like particles (VLPs) have shown the ability to induce a robust immune response(321-324). 
Self-assembling protein nanoparticles (SAPNs) are built by monomeric protein chains composed 
of coiled-coil oligomerization domains, in which the polymerization of peptide monomers is 
dictated by the intrinsic property of coiled-coil domains(280, 281). SAPNs are a biodegradable 
biomaterial with mechanical and chemical stability, which are well suited to repetitively present 
multiple antigenic epitopes linked to the N or C terminus of the coiled-coil domains, particularly 
in a conformation-specific manner(281).  SAPNs have the capability of eliciting long lasting 
antibody and cellular immune responses against a parasite from the genus Plasmodium, the 
causative parasite of malaria(277), but also are able to flexibly carry a built-in protein immune 
modulator as an adjuvant(246). The potential to induce a long lasting humoral and cellular immune 
response while displaying self-adjuvanting properties makes SAPNs a powerful platform in 
designing a universal AI vaccine.  
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In our previous studies, we have developed two versions of vaccine prototypes for avian 
influenza based on the SAPNs technology. The first SAPNs version was constructed by co-
expressing nanoparticle core sequence and M2e linked to the N-terminus of a tetrameric coiled-
coil domain(245), in which M2e is a conserved transmembrane protein across avian and mammal 
influenza viruses(325). The SAPNs repetitively displayed M2e on the surface in its native 
tetrameric conformation state, showing its efficacy in reducing virus shedding in chickens co-
administered of the SAPN with Freund’s adjuvant after challenge with a low pathogenic avian 
influenza virus (A/Turkey/CA/D0208651-C/02 H5N2) (245). To further improve the 
immunogenicity of the first version of SAPNs(245), we have added our second version SAPNs 
named SA-MC-Penn with the conserved epitope Hel C from the stalk region of hemagglutinin 
(HA), an epitope that has been demonstrated to induce broad neutralizing antibodies(302). In 
addition, to make SA-MC-Penn self-adjuvanted, we added conserved D0 and D1domains of 
flagellin molecule from Salmonella entericaserovar Typhimuriumat the C terminus(246). Flagellin, 
a well-characterized molecular adjuvant, has been shown to improve the immunogenicity of 
vaccines(299, 326).  In our SAPNs, the displayed flagellin domains interact with toll-like receptor 
5 on the membrane of antigen presenting cells, interconnecting innate immunity and adaptive 
immunity, thus enhancing the presentation of vaccine immunogens(327). We have shown our 
second iteration of design SA-MC-Penn induced high level of cross-neutralizing antibodies in 
immunized chickens(246). Moreover, upon immunization of mice with the SAPNs based vaccine, 
namely SA-MC-PR8 presenting the H1N1 B cell epitopes, mice were completely protected from 
lethal challenge with H1N1 (A/Human/Puerto Rico/8/1934) (246).  However, the efficacy of SA-
MC-Penn to protect chickens from a HP AIV challenge has yet to have been determined.  Thus, 
this study was performed to evaluate the efficacy of SA-MC-Penn SAPNs vaccinated chickens to 
be protected from an H5N2 HP AIV (A/chicken/ Pennsylvania/1/1983) challenge.  
3.2 Materials and Methods 
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3.2.1 Virus, animals and immunization 
Duplicate groups of 14 specific pathogen free (SPF) white leghorn chickens at four-weeks 
of age (Charles River Laboratories, Wilmington, MA) were vaccinated three times with the 
previously optimized dose (immunogenicity study data not shown) of 100 µg of the SAPN SA-
MC-Penn via the intramuscular (IM) or eye drop (ED) routes.  For comparative purposes, a 
commercial oil adjuvanted H5N2 vaccine of 0.5mL (Dodge Fort) was given (IM) three times at the 
same intervals as a control for the SAPN treatments following the manufacturers’ recommendations.  
Two groups of 14, non-vaccinated chickens were included as negative and challenge controls.  
Serum samples were collected from all birds at day 32 post vaccination.    All birds in one of each 
treatment group were challenged with the HP AIV strain A/chicken/Pennsylvania/1/1983 (H5N2) 
by intranasal instillation of 104 embryo infectious dose50% (EID50) and were observed for 14 
days.  Oropharyngeal (OP) and cloacal swabbing were collected 2, 4, 7, 10 and 14 days-post 
challenge (PC). All chickens had access to feed and water ad libitum. Chickens unable to reach 
food and/or water were euthanized in accordance with the protocol approved by the University of 
Delaware Institutional Animal and Care Use Committee Gelb (9) 09-09-11R.  
3.2.2 ELISA and quantitative real time RT-PCR 
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ELISA assay was performed to evaluate the antibody response. Briefly, chicken sera were 
serial diluted (2-fold dilutions) and raised against the ELISA plates coated with 1 µg/mL of the 
SAPN SA-MC-Penn and incubated for one-hour at room temperature (RT).  Plates were washed 
3× with PBST buffer (1× PBS, 0.05% Tween).  Secondary antibody, anti-chicken Ig Y (1: 1000 
in1×PBS/3%BSA), was added and incubated for one-hour at RT.  Plates were washed 3x with 
PBST.  Plates were developed   by the addition of TMB developing solution (Thermo Scientific, 
USA) for 10 min for color development. Reaction was stopped by adding 50µL of 0.5 M sulfuric 
acid. Colorimetric changes in each well were detected at 450nm using a BioTek microplate reader. 
A cutoff point for a positive reaction by ELISA test was set the OD value at 450nm of a tested 
serum 3X times the negative control serum. 
RNA extracted from OP swabs was quantified by quantitative real-time RT-PCR using the 
Qiagen one-step RT-PCR kit according to the protocol described by Spackman et al(328). Briefly, 
the primers and probe were used in the reaction as follows: forward primer-5’ACG TAT GAC TAT 
CCA CAA TAC TCA G3’; reverse primer-5’ AGA CCA GCT ACC ATG ATT GC 3’; probe- 
FAM-TCA ACA GTG GCG AGT TCC CTA GCA-TAMRA. The reaction was conducted with a 
RT profile setting for 30 min at 50°C and 15 min at 94°C, and a H5-specific PCR for 40 cycles as 
follows: 94°C for 0 s, 57°C for 20 s, and 72°C for 5 s.  
  
3.2.3 Statistics 
Data was analyzed using two-way ANOVA with Bonnferoni post-test in Graphpad Prism 6.0. 
Statistical significance was achieved at levels of P values <0.05 (*), <0.01 (**), and <0.0001 (***). 
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3.3 Results 
3.3.1 SA-MC-Penn elicited antibody response against AIV-M2e and Helix C 
To evaluate the serum antibody responses, sera harvested at 10 weeks of age, 2 weeks after 
the third vaccination, were evaluated by ELISA in plates were coated with 1µg/mL SA-MC-Penn.  
Chickens immunized IM with 100 µg SA-MC-Penn (Figure 3.1 red line) developed highest level 
of detectable antibodies compared to chickens vaccinated with the 0.5mL inactivated commercial 
vaccine IM route (Figure 3.1 blue line) or the 100 µg SA-MC-Penn ED route (Figure 3.1 green 
line). No antibodies were detected in non-vaccinated chickens (Figure 3.1 red line).  The data 
showed that the IM route was superior to the ED route of immunization with the SAPNs vaccine, 
as it elicited higher levels of serum antibodies.    
3.3.2 SA-MC-Penn nanoparticle vaccine prototype offered partially protection against 
HPAIV H5N2 challenge. 
Sixty percent of non-vaccinated chickens succumbed to infection by day 6 PC (Figure 3.2). 
In comparison, chickens immunized with 100 µg SA-MC-Penn via the IM or ED route showed a 
prolonged period of survival after challenge compared to the challenge control chickens. At 14 
days PC, 63% and 30% chickens survived in SA-MC-Penn IM and ED route vaccinated groups, 
respectively, numerically greater survival rates than the challenge control chickens.  The survival 
chickens vaccinated via the IM route were twice that of the ED route and 3x that of chickens in the 
challenge control group.  However, all chickens that received the commercial inactivated vaccine 
survived challenge.   
3.3.3 SA-MC-Penn reduced viral shedding in immunized chickens 
Virus shedding from the respiratory (oral) and digestive tracts were evaluated by 
performing real time RT-PCR screening of OP and cloacal swabbings, respectively (Figure 3.3).  
Compared to non-vaccinated and challenged chickens, OP swabs collected from IM or ED SA-
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MC-Penn vaccinated chickens showed decreased virus shedding 2, 4 and 14 days PC.  Oral virus 
shedding was generally numerically lower in chickens vaccinated with SA-MC-Penn by the IM 
route compared to the ED route.  A significant (P<0.05) reduction of one logarithm was observed 
in OP swabs collected from chickens vaccinated via the IM route with SA-MC-Penn at 2 days p.c. 
(Figure 3.3A). No significant reduction of cloacal virus shedding was observed in chickens 
vaccinated by either route with SA-MC-Penn (Figure 3.3B).  Chickens receiving the commercial 
inactivated H5N2 vaccine significantly (P<0.05) reduced virus shedding from the respiratory and 
digestive tracts at all the time points as compared to the no vaccine group and the IM or ED SA-
MC-Penn groups.  
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3.4. Discussion and conclusion 
The potential to undergo continuous and rapid evolution of the genes encoding the HA and 
neuraminidase (NA) envelope proteins, both found on the surface of AIV, impact the development 
of effective vaccines for avian and mammalian species.  Traditional vaccines are challenged by 
their effectiveness when the genetic profile of currently circulating strains of AIV change.  More 
importantly, live attenuated vaccines are not utilized due to the possibility of reversion to virulence. 
In our previous studies, the SAPNs were successfully used as a delivery system for AIV protein.  
M2e and Helix C, AIV epitopes, can be repetitively displayed on SAPNs surface as a tetramer and 
trimer, respectively, which are native conformations in the AIV capsid(246).  Importantly, flagellin 
was co-assembled as a part of the SAPNs SA-MC-Penn to increase interaction with dendritic cells 
via TLR 5 on cellular membranes and subsequently improve antigen presentation.  Inclusion of 
flagellin gave the SAPNs the self-adjuvanted properties.  Our previous studies demonstrated 
SAPNs vaccine prototypes induced levels of antibodies, especially cross-reactive antibodies, 
against AIV and more importantly, provided protection against LPAIV in chickens(245, 246).  
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In this study, we demonstrated SA-MC-Penn partially protected chickens from challenge 
with an HP H5N2 strain of AIV.  Route of administration can directly impact the efficacy of a 
vaccine(329).  Most currently available vaccines for AIV are inactivated vaccines and are 
administered parenterally(220). In contrast, ED route of vaccine administration takes less effort. 
Moreover, ED administration stimulates the local lymphoid organ called Harderian gland located 
within the eye sac(120). It has been proved an effective strategy to administrate inactivated AI 
vaccine inducing significantly systemic Ig G that protected chickens against HP AI(330). However, 
our data showed ED was less antigenic (Figure 3.1) and protective (Figure 3.2) than the IM route.  
One possible reason for the impact on the effectiveness of SA-MC-Penn by IM or ED routes of 
administration could be due to a higher efficiency of vaccine-take of soluble protein antigen SA-
MC-Penn via IM route than did ED route at the sites of inoculation. Numerically lower viral 
shedding from the oral cavity was observed in chickens vaccinated via the IM route vs. the ED 
route.  
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Vaccine group treated with whole virus inactivated vaccine with oil-emulsion showed complete 
protection against HP AIV challenge, and significantly (P<0.05) lower OP and cloacal virus 
shedding as compared to all other treatment group.  This finding was not surprising since the whole 
AIV inactivated vaccine contains all antigenic epitopes capable of inducing a strong immune 
response.  The presence of the virus and adjuvant in the inactivated virus vaccine strongly 
stimulated humoral immunity and further maximize the adaptive immune responses(220, 331). In 
comparison, SA-MC-Penn, a viral subunit SAPNs vaccine, achieved 63% livibility when it was 
administered without additional adjuvants.  Although the protection less than the whole virus 
inactivated vaccine, the subunit SAPNs vaccine demonstrated self-adjuvanted characteristics, 
which was in agreement with the previous malaria SAPNs vaccine prototype (277). The adjuvant 
effect might be attributed to hydrophobic coiled-coil domains of protein-based polymers as well as 
the flagellin domains displayed on the SAPNs(332, 333). Our data also supports the long-standing 
concept that the application of flagellin as adjuvant in vaccine formulation(326, 333).  
Results from this study show that further optimization of experimental SAPNs vaccine SA-
MC-Penn is required.  The data suggest that a higher dose of SA-MC-Penn SPANs may be required 
to achieve protection similar to the whole virus inactivated vaccine.  In addition, cellular immunity 
is required for the clearance of virus infection(128, 129).  Therefore, the SAPNs vaccine may be 
improved by the addition of conserved T cell epitopes from the AIV nuclear protein.  Adding such 
epitopes may stimulate cellular immunity against AIV thus reducing viral shedding.  
 To conclude, chickens immunized with the SAPNs SA-MC-Penn prototype vaccine 
administered without a commercial adjuvant were partially protected from challenge with the 
H5N2 HPAIV strain A/chicken/Pennsylvania/1/1983.  
 
3.5 Contributions 
Dr. Peter Burkhard designed all SAPNs. Dr. Christopher Karch produced and physically 
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characterized all SAPNs in Dr. Peter Burkhard’s laboratory. Jianping Li performed all ELISA 
tested. Challenge study and qReal time RT-PCR was conducted by Dr. Brian Ladman and Dr. 
Jack Gelb, Jr at the University of Delaware. 
 
Figure 3. 1 Evaluation of antibody response by ELISA.  
Antibody detection by ELISA with pooled sera harvest from chickens at two weeks post second 
boost vaccination; Black line: no vaccine group; Blue line: Chickens group vaccinated with 0.5cc 
inactivated H5N2 vaccine; Red line: vaccinated chickens with100 µg SA-MC-Penn via IM Green 
line: chickens vaccinated with100 µg SA-MC-Penn via ED route.
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Figure 3. 2 Survival rates of vaccinated chickens against H5N2 HPAIV subtype challenge. 
Chickens survive against HP AI post challenge at 2, 4, 7, 10 and 14 days. Black: survival of 
unvaccinated chickens. Red: survival of chickens vaccinated IM with100 µg SA-MC-Penn. Green: 
survival of chickens vaccinated with100 µg SA-MC-Penn via ED route. Blue: survival of 
vaccinated chickens with 0.5cc inactivated H5N2 vaccine. 
 
 
 
Figure 3. 3 Virus shedding after challenges (A): Oropharengeal virus load and (B): Cloacal 
virus shedding   
Evaluation of virus shedding in OP and cloacal swab samples by real time RT-PCR. Black: no 
vaccine group. Red: Chickens group vaccinated intramuscularly with100 µg SA-MC-Penn. Green: 
Chickens groups vaccinated with100 µg SA-MC-Penn via eye drop route. Blue: Chickens group 
vaccinated with 0.5cc inactivated H5N2 vaccine, * was significantly different (P < 0.05), ** was 
significantly different (P < 0.01). *** was significantly different (P< 0.001) 
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Chapter 4 Evaluation of the effect of commercial adjuvants on the SAPN 
vaccine for avian influenza virus 
 
Abstract 
Protein subunit vaccines tend to be less immunogenic when administered alone as 
compared to a vaccine constituent integrated with an adjuvant. To improve our SAPN vaccine SA-
MC-Penn, the immunoadjuvanticity of four commercial adjuvants: unmethylated cytosine-guanine 
dinucleotide-containing oligodeoxynucleotides (CpG ODN), MONTANIDETM IMS 1313 VG N 
(IMS), MONTANIDETM GEL 01 (Gel) and Monophosphoryl Lipid A (MPLA) were evaluated. All 
tested adjuvants were able to enhance overall antibody responses to SA-MC-Penn. MPLA was the 
most effective one when co-administered with SA-MC-Penn. Chickens vaccinated with SA-MC-
Penn combining MPLA had significant enhancement of neutralizing antibodies and had significant 
reduction of virus shedding while chickens co-administered SA-MC-Penn with and the other 3 
adjuvants shown no protection against challenge with a low pathogenic avian influenza virus strain 
H5N2.  
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4.1 Introduction 
Avian influenza (AI) is a devastating poultry disease that causes high mortality, leading to 
economic loss in the poultry industry and in some cases; some strains may pose a public health 
concern of causing human infections(25). In some countries other than the US, vaccination is 
utilized for disease control of AI(291). However, designing an effective vaccine against AI is 
challenging due to the highly mutable genome of the avian influenza virus (AIV) (308). One 
practical strategy is to develop a universal vaccine comprising   multiple conserved epitopes against 
a wide range of AIV strains(308, 319).  
In recent years, designing novel biodegradable nanomaterials with well-defined structures 
that modulate immune responses has attracted substantial attention in vaccine development(320). 
To improve drug delivery, nanosized lipid or polymer-based particle, liposomes, virosomes and 
virus-like particles (VLPs) have demonstrated an ability to induce robust immune responses(321). 
Self-assembling protein nanoparticles (SAPNs) are built by monomeric protein chains composed 
of coiled-coil oligomerization domains, in which the polymerization of peptide monomers is 
dictated by the intrinsic property of coiled-coil domains. SAPNs are a biodegradable biomaterial 
with mechanical and chemical stability, which are well suited to repetitively present multiple 
antigenic epitopes linked to the N or C terminus of the coiled-coil domains, particularly in a 
conformation-specific manner(334). SAPNs not only have the capability of eliciting long lasting 
antibody and cellular immune responses(335) but also are able to flexibly carry a built-in protein 
immune modulator as adjuvant(246). These advantages make SAPNs a powerful platform in 
designing a universal AI vaccine.  
We have developed a self-adjuvanted SAPN vaccine namely SA-MC-Penn. Immunization 
of SA-MC-Penn via intramuscular (IM) or eye-drop (ED) route provided protection from 
homologous challenge with a highly pathogenic avian influenza virus (HPAIV) 
A/chicken/Pennsylvania/1/1983 (H5N2) in chickens. Upon challenge with highly pathogenic (HP) 
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AIV, 63 % and 30% of chickens the SAPN IM and SAPN ED groups, respectively, survived. It 
suggested further optimization of experimental vaccine formulation SA-MC-Penn SAPNis 
required. Therefore, to enhance the immunogenicity of SA-MC-Penn, in this study, we tested a 
broad range of commercial adjuvants in addition to SA-MC-Penn formulation, including 
unmethylated cytosine-guanine dinucleotide-containing oligodeoxynucleotides (CpG ODN) 
(Invivogen, ODN2006), MONTANIDETM IMS 1313 VG N (IMS), MONTANIDETM GEL 01 (Gel) 
and Monophosphoryl Lipid A (MPLA).   
4.2 Materials and Methods 
4.2.1 Bioproduction and characterization of SA-MC-Penn SAPN vaccine 
 SA-MC-Penn was produced and was characterized as previously described in chapter 2.  
4.2.2 Cell lines and virus 
TLR5 SEAPorter cell line (Novus Biologicals, Littleton, CO) was maintained as per 
manufacturer's instructions. Madin–Darby canine kidney (MDCK) cells were cultured in the MEM 
medium (GIBCO) supplemented with 4 mM L-Glutamine (GIBCO) and 10% fetal bovine serum 
(FBS) (HyClone) in a humidified incubator with 5% CO2 at 37 °C. Low pathogenic H5N2 virus 
(A/Turkey/CA/D0208651-C/02) were propagated in 9-day-old embryonating specific pathogen–
free (SPF) chicken eggs for 3 days. 
4.2.3 Animals, Immunization and challenge 
Groups of 3 or 5 specific pathogen free (SPF) white leghorn chickens (Charles River, 
Norwich, CT) at 4-weeks age were co-administered three times with 100 µg of the SAPN SA-MC-
Penn and different types of commercial adjuvants or were given with adjuvants alone as described 
in table 4.1. Each inoculation was conducted every two weeks. Sera were harvested at 6, 8 and 10 
weeks of age. At 10 weeks of age, chickens were challenged with the low pathogenic avian 
influenza virus (LPAIV) strain H5N2 (A/Turkey/CA/D0208651-C/02) through intranasal 
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instillation of 1.7x107 plaque forming units (pfu). Chickens were observed for 8 days. 
Oropharyngeal (OP) and cloacal swabbing were collected 4 and 8 days-post challenge. At the 
endpoint of the study, chickens were euthanized in accordance with the protocol approved by the 
University of Connecticut Institutional Animal and Care Use Committee.  
4.2.4 Enzyme-linked Immunosorbent Assay (ELISA) 
ELISA plates (Thermo Scientific) were coated with 50 µL of 1 µg/mL peptide antigen in 
carbonate-bicarbonate buffer overnight at 4 °C. Plates were blocked with 100 µL of 3% BSA in 
PBST solution (PBS plus 0.05% Tween 20). Serial diluted sera starting at 1/100 in 50 µL were 
incubated against the plates at room temperature for 1 hour. Mouse anti-chicken Ig Y followed and 
was added to the plates at 1/1000 dilution at room temperature for 1 hour. 50 µL TMB (Thermo 
scientific) was applied to develop plates at room temperature for 5-15 minutes until color 
developed.  Reactions were stopped with 0.01% HCl. Plates were read for absorbance of optical 
density at 450nm. Dilution endpoints were read until absorbance of optical density reaches 0.2 at 
OD450nm. 
4.2.4 Plaque reduction assay 
One hundred PFUs of low pathogenic H5N2 (A/Turkey/CA/D0208651-C/02) were mixed 
with diluted anti-sera in incubator at 37ºC for 1h. Virus-sera mixture was inoculated onto confluent 
MDCK cellular monolayer on 61 cm-plates. Sera-virus mixture was incubated with MDCK cells 
in the incubator at 37ºC with 5% CO2 for 1 hour. Plates were washed for 3 times and overlayed 
with 2X MEM containing 0.8% agarose, 2 µg/mL TPCK-treated trypsin (Sigma, USA) and 1X 
Fungizone. Cells were incubated in a humidified incubator at 5% CO2 at 37ºC for 3 days. Plates 
were fixed with 10% neutral formalin and stained with 0.01% Crystal violet stain to visualize 
plaques. 
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4.2.5 Quantitative real time RT-PCR 
First strand cDNA in a reverse transcription reaction (RT) was synthesized using Applied 
Biosystem kit. 800 ng of total RNA was used in a 20µL reaction containing 0.8µL dNTP, 2 µL 
reaction buffer, 2 µL H5 M gene specific reverse primer (TGC AAA AAC ATC TTC AAG TCT 
CTG) and 1 µL enzyme mix according to the manufacturer’s instruction. RT reaction was 
conducted in a thermocycler with a programmed profile of 26°C for 10 min, 42°C for 45 min, 75°C 
for 10 min and 4°C-∞. 2µL cDNA was used in a real time RT-PCR reaction. Reaction mix was 
prepared according to the manufacturer’s instruction (Biotool), including 0.4µL SYBR green dye, 
0.1 µL of 100 µM forward and reverse primers (Forward primer: AGA TGA GTC TTC TAA CCG 
AGG TCG;	Reverse primer: TGC AAA AAC ATC TTC AAG TCT) 10 µL 2X reaction buffer 
containing polymerase and dNTPs, and 7.4 µL ddH2O. Reaction was run with a Bio-Rad real time 
system CFX 96 with a cycling profile, at 95 °C for 10 min, and 40 cycles at 95°C for 3s, and 60 °C 
for 30 s. Melting temperature was determined from 65 °C to 95 °C with heating ramp of 0.5 °C/s.  
4.2.6 Statistical Analysis  
Multiple comparisons between experimental groups in comparison of viral shedding was 
made by repeated measure two-way ANOVA. Bonferroni was done to compare mean values of each 
group. P<0.05 is considered as statistically significant. All statistical analyses were done in 
GraphPad 5.0 (San Diego, CA).  
4.3 Results 
4.3.1 Adjuvants CpG ODN206, MONTANIDETM IMS 1313 VG N, MONTANIDETM GEL 
01 and Monophosphoryl Lipid A promoted an elevated antibody response induced by SA-
MC-Penn SAPN vaccine 
In this study, we determined whether commercial adjuvants (CpG ODN2006, IMS, Gel 
and MPLA) could enhance the antibody responses of SAPN vaccine construct SA-MC-Penn in 
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chickens. To address this question, specific pathogen free (SPF) white leghorn chickens at 4 weeks 
of age were immunized with SA-MC-Penn co-administrated with or without tested adjuvants 
described in table 4.1. Control chickens were inoculated with tested adjuvants alone in buffer as 
described in table 4.1. Two immunization boosts were conducted at 6 and 8 weeks of age. Sera 
were collected 6, 8 and 10 weeks of age post each immunization. The ELISA tests were used to 
assess the humoral immune responses in immunized chickens. Chickens given SA-MC-Penn alone 
showed a moderate level of antibody responses reaching the peak two weeks post second dose of 
immunization. There was no boosting effect between the second dose and third dose (Figure 4.1A). 
SA-MC-Penn co-administered with either CpG or Gel promoted evaluation of antibody levels 
reaching the peak post 1 dose of vaccine but no boosting effect was observed (Figure 4.1 B and D). 
By contrast, clear boosting effects on the elevation of antibody revels were observed in chickens 
immunized with SA-MC-Penn while co-administered with either IMS or MPLA (Figure 4.1 C and 
E). These results suggested that the addition of the four adjuvants generally promoted an elevation 
of an antibody response. 
4.3.2 Induction of neutralizing antibodies by SA-MC-Penn in vaccinated chickens co-
administered with the adjuvants 
 To determine the presence of neutralizing antibodies, a plaque reduction assay was 
performed to evaluate the virus neutralization against LPHAIV H5N2 on MDCK cells in vitro. Co-
administration of SA-MC-Penn with MPLA induced anti-sera harvested from chickens at 2 weeks 
post first boost showing 59.61% virus neutralization, which was significantly higher than did co-
administration of SA-MC-Penn with either CpG or Gel showing 21.38% and 35.2% neutralization, 
respectively (Figure 4.2). IMS also promoted a significant elevation of neutralizing antibodies’ 
level when compared to the immunized chickens receiving the vaccine containing CpG at 2weeks 
post first boost (Figure 4.2). However, the levels of neutralizing antibodies in vaccine groups 
receiving either IMS or MPLA decreased at 2 weeks post second boost (Figure 4.2). These results 
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suggested that MPLA would be the best candidate as an adjuvant in a vaccine formulation of SA-
MC-Penn as compared to the other three adjuvants.  
4.3.3 Effect of SA-MC-Penn SAPN vaccine on viral shedding while co-administered with the 
adjuvants 
 Efficacy of SA-MC-Penn SAPN vaccine against challenge with a LPHAIV strain H5N2 
(A/Turkey/CA/D0208651-C/02) was evaluated while it was co-administered with the four 
adjuvants. Quantitative real time RT-PCR was used to measure Oropharyngeal (OP) and cloacal 
shedding of the virus in the vaccinated and challenge control chickens 4 and 8 days post challenge. 
Reductions of both OP and cloacl shedding were shown in chickens given the SA-MC-Penn SAPN 
vaccine and MPLA adjuvants as comparing to the challenge control chickens at 4 and 8 days after 
challenge (Figure 4.3 G and H). Significant reduction was observed in OP shedding from 
vaccinated chickens co-administered with MPLA (Figure 4.3 G). There was no significant 
reduction of oropharyngeal and clocal shedding observed in vaccine groups while co-administered 
with CpG, IMS and Gel, respectively (Figure 4.3 A-F).  
4.4 Discussion 
Prophylactic subunit vaccines tend to be less immunogenic while administered without 
adjuvants(336, 337). Adjuvant integrated with vaccine immunogens augments the immunogenicity 
through a broad range of mechanisms of action, including depot effect, enhancement of antigen 
presentation, influence on the secretion of immunostimulatory cytokines, triggering innate 
immunity and the interconnected adaptive immune responses to antigen and promoting mucosal 
responses(338). Thus, combining an appropriate adjuvant with a vaccine could be an effective 
approach to improve vaccine efficacy. In our previous work, we have shown our SAPN vaccine 
SA-MC-Penn containing a well-defined molecular adjuvant TLR5 agonist has only achieved partial 
protection from a challenge against an HPAIV strain (A/chicken/Pennsylvania/1/1983 (H5N2) in 
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chickens. To improve the vaccine efficacy of SA-MC-Penn, we have explored to test a broad range 
of commercial adjuvants that were integrated with the tested vaccine, including CpG ODN 2006, 
Montanide IMS, Montanide Gel 01 and MPLA. 
 CpG ODN is well-defined molecular adjuvant and has been extensively tested as a vaccine 
adjuvant in different models against infectious diseases(339). The mechanism of action of CpG 
adjuvancity is through the activation of cells that express pattern recognition receptors, TLR 9(340) 
or TLR 21(341)in mammalian or in avian models respectively, resulting in the secretion of 
inflammatory cytokines and type I interferon required for the activation of humoral and cellular 
immunity(342, 343). Various observations were reported that co-administration of CpG ODN with 
AI vaccines of either inactivated whole virus or virosome in chickens significantly enhanced the 
secretion of IgA, elevated level of serum Ig Y, increased survival, reduced virus shedding, and 
promoted the production of cytokines including IFN-γ, IFN-α, IL-6, IL-8 and IL-12(344-349). In 
addition, CpG ODN administrated alone within 24 hours prior to challenge showed prophylactic 
effect on significantly reducing AI virus shedding(350, 351).  Our work agreed with the previous 
observation of the enhancement of antibody responses when combining CpG ODN 2006 in our SA-
MC-Penn SAPN vaccine (Figure 4.1B). Importantly, the vaccine group which received CpG ODN 
2006 had elevated neutralizing antibody level after boost while vaccine groups given with the other 
three adjuvants showed decreasing neutralizing antibodies (Figure 4.2). It suggested that CpG ODN 
2006 might play more important roles in the process of antibody affinity maturation, consistent 
with the fact that CpG ODN mediated differentiation of antigen-specific B cells into plasma B 
cells(352). Conversely, our study didn’t show any adjuvanting effect on the reduction of virus 
shedding of the AI virus 4 and 8 days post challenge (Figure 4.3 A and B). Our results suggested 
that CpG might not be compatible with SA-MC-Penn SAPN and was not able to synchronize with 
flagellin molecules in the SAPN for the enhancement of adjuvanticity. One reason accounting for 
the low adjuvanticity of CpG ODN 2006 might be the interference of flagellin in the SAPN vaccine. 
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Another reason might be unresponsiveness to CpG ODN 2006 in chickens. Although CpG ODN 
has been experimentally successful in whole virus or virosome vaccines for AI, it requires further 
investigation the effect of CpG as an adjuvant on the efficacy of an AI subunit vaccine.  
MONTANIDETM IMS 1313 VG N (IMS) is a nanoparticle-based adjuvant containing 
immunostimulatory compounds. IMS has been widely tested for poultry medicine. It has been 
shown the use of IMS in a subunit vaccine induced increasing IgA and Ig Y response and provided 
protection against avian	 coccidiosis(353-355). Besides, co-administration of IMS has been 
demonstrated to the improvement of the efficacy of a live vaccine for avian infectious 
bronchitis(356). Limited information of the use of IMS integrated with AI vaccine was reported. 
Recently, EI Naggar et al demonstrated IMS enhanced the cell-mediated immunity of an mucosal-
based inactivated AI vaccine by increasing phagocytic activity, promoting the production of IL-6 
and IFN γ, and provided protection from challenge(357). In addition to this observation, we 
demonstrated the addition of IMS in our SAPN vaccine enhanced the immunogenicity of the 
subunit vaccine in the regard of antibody production (Figure 4.1 C).  A non-lasting, intermediate 
level of neutralizing antibodies was observed (Figure 4.2). As compared to EI Naggar et al’s 
observation, our results showed no reduction of virus shedding (Figure 4.3 C and D), suggesting 
that IMS is not potent enough for subunit vaccine for AI.   
The use of MONTANIDETM GEL 01 in vaccine formulation for AI in poultry is also 
limited to inactivated whole virus vaccine. Lone et al recently have shown co-administration Gel 
with an inactivated H7N3 vaccine enhanced the survival rate of chickens challenged with a LPAIV 
A/chicken/British Columbia/314514-1/2004 H7N3(358). In our study, chickens receiving SAPN 
vaccine SA-MC-Penn combining the Gel adjuvant had enhanced titers of overall antibodies (Figure 
4.1D) but relatively low titers of neutralizing antibodies (Figure 4.2). Yet, the enhanced humoral 
immunity failed to reduce virus shedding (Figure 4.3 E and F), suggesting Gel is not a suitable 
adjuvant for our SAPN vaccine. 
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MPLA is another molecular adjuvant with a well-characterized mechanism of action 
through the activation of its receptor TLR 4 signaling(359). The use of TLR-4 ligand in 
recombinant subunit vaccines for influenza has demonstrated broadly protective in mice(360).  In 
poultry, another TLR-4 ligand lipopolysaccharide (LPS) has been demonstrated its prophylactic 
effect against challenge with a strain LPAI A/Duck/Czech/56 (H4N6) (350). In our study, 
immunization of SA-MC-Penn combining MPLA in chickens induced a pronounced increase of 
antibody responses (Figure 4.1 E). As comparing to the other tested adjuvants, MPLA significantly 
enhanced the production of neutralizing antibodies (Figure 4.2). Importantly, administration of SA-
MC-Penn constituted with MPLA in chickens reduced OP and cloacal shedding of virus 4 and 8 
days post challenge (Figure 4.3 G and H). The reduction of OP shedding was significant (Figure 
4.3 G). Collectively, MPLA is a suitable adjuvant when co-administered with our SA-MC-Penn 
SAPN vaccine. 
4.5 Contributions 
Dr. Peter Burkhard designed all SAPNs. Dr. Christopher Karch produced and physically 
characterized all SAPNs in Dr. Peter Burkhard’s laboratory. Jianping Li performed all in vitro and 
in vivo studies to evaluate the immunogenicity and efficacy SAPN vaccine candidates in chicken 
model challenged with LPAIV. 
 
 
Table 4. 1Table 4.1 Treatments of immunization 
Groups (n=numbers of 
chickens) 
SAPN 
concentration / 
chicken/dose 
 Adjuvant 
concentration/chicken/do
se  
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SA-MC-Penn/CpG ODN2006 
(n=5) 
100µg 25 µg CpG ODN2006 
CpG ODN2006/Buffer (n=3) --- 25 µg CpG ODN2006 
SA-MC-Penn/ MONTANIDETM 
IMS 1313 VG N (n=5) 
100ug	 50 % MONTANIDETM 
IMS 1313 VG N 
MONTANIDETM IMS 1313 VG 
N/buffer (n=3) 
--- 50 % MONTANIDETM 
IMS 1313 VG N 
SA-MC-Penn/ MONTANIDETM 
GEL 01 (n=5) 
100ug	 10 % MONTANIDETM 
GEL 01 
MONTANIDETM GEL 01/Buffer 
(n=3) 
--- 10% MONTANIDETM 
GEL 01 
SA-MC-Penn/MPLA 100ug	 0.2 µg (MPLA) 
MPLA/Buffer ---	 0.2 µg (MPLA) 
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Figure 4. 1 Antibody responses to SA-MC-Penn vaccine. 
Sera collected from chickens in each treatment group at 2weeks after each dose of immunization 
were serial diluted and raised against ELISA plate coated 1 µg/mL MC-Penn. Optical density at 
450nm was measured to represent antibody titers. Treatment groups:  A: 100 µg SA-MC-Penn 
alone; B: 100 µg SA-MC-Penn and 25 µg CpG ODN206; C: 100 µg SA-MC-Penn and 50% 
MONTANIDETM IMS 1313 VG N; D: 100 µg SA-MC-Penn and 10 % MONTANIDETM GEL 01; 
E: 100 µg SA-MC-Penn and 0.2 µg Monophosphoryl Lipid A. 
ELISA SA-MC-Penn/IMS
1/1
00
1/2
00
1/4
00
1/8
00
1/1
60
0
1/3
20
0
1/6
40
0
1/1
28
00
1/2
56
00
1/5
12
00
1/1
02
40
0
1/2
04
80
0
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0 2 weeks post 1st dose
2 weeks post 2nd dose
2 weeks post 3rd dose
C
O
D
45
0
ELISA SA-MC-Penn/Gel
1/1
00
1/2
00
1/4
00
1/8
00
1/1
60
0
1/3
20
0
1/6
40
0
1/1
28
00
1/2
56
00
1/5
12
00
1/1
02
40
0
1/2
04
80
0
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0 2 weeks post 1st dose
2 weeks post 2nd dose
2 weeks post 3rd dose
D
O
D
45
0
SA-MC-Penn/MPLA
1/1
00
1/2
00
1/4
00
1/8
00
1/1
60
0
1/3
20
0
1/6
40
0
1/1
28
00
1/2
56
00
1/5
12
00
1/1
02
40
0
1/2
04
80
0
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
2 weeks post 1st dose
2 weeks post 2nd dose
2 weeks post 3rd dose
E
O
D
45
0
		 89 
 
Figure 4. 2 SA-MC-Penn SAPN vaccine induced the production of neutralizing antibodies.  
Anti-sera of vaccine group co-administered 4 different adjuvants (CpG, IMS, Gel and MPLA), 
respectively, were collected at time points of 2weeks post 1st and 2nd boost immunization. Anti-sera 
were pooled to evaluate the virus neutralization on LPAIV H5N2 in vitro. Percentage of 
neutralization resulted from sera from vaccinated animals was calculated from % of plaque 
reduction as compared to sera from refolding buffer vaccinated animals (negative sera). 
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Figure 4. 3 virus shedding in chickens after challenge.  
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Oropharyngeal (un-striped columns) and cloacal (striped columns) swab samples were collected 
from chickens 4 and 8 days post challenge. Quantitative real time RT-PCR was performed to 
quantify viral shedding. A&B: oropharyngeal and cloacal shedding from chickens those were 
administered with CpG ODN206 alone, SA-MC-Penn and CpG ODN206, or MC-Penn and CpG 
ODN206, respectively; C&D: oropharyngeal and cloacal shedding from chickens those were 
administered with MONTANIDETM IMS 1313 VG N alone, or were co-administered with SA-MC-
Penn and MONTANIDETM IMS 1313 VG N; E&F, oropharyngeal and cloacal shedding from 
chickens those were administered with MONTANIDETM GEL 01 alone, or were co-administered 
with SA-MC-Penn and MONTANIDETM GEL 01; G&H: oropharyngeal and cloacal shedding from 
chickens those were administered with MPLA alone, or were co-administered with SA-MC-Penn 
and MPLA. 
Chapter 5. Nanoparticulate vaccine delivery systems tailor immune 
responses against infection of infectious bronchitis virus in chickens  
Abstract 
Infectious bronchitis virus (IBV) affects poultry respiratory, renal and reproductive 
systems. Currently the efficacy of available live attenuated or killed vaccines against IBV has been 
challenged. We designed a novel IBV vaccine alternative using a highly innovative platform called 
Self-ssembling Protein Nanoparticle (SAPN). We repetitively presented B cell epitopes derived 
from the second heptad repeat (HR2) region of IBV spike proteins in its native conformation of 
trimeric state. In addition, we also co-displayed flagellin in the SAPN to achieve a self-adjuvanted 
effect. Three groups of chickens were inoculated at 4-weeks of age with the vaccine prototype, 
IBV-Flagellin SAPN, a buffer control, or a negative-control construct Flagellin-only SAPN. The 
immunized chickens were challenged with 5x104.7 EID50 IBV M41 strain. A higher antibody titer 
was detected in chickens immunized with IBV-Flagellin SAPN compared to chickens that were 
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given Flagellin-only SAPN. Ex vivo proliferation of peripheral mononuclear cells (PBMCs) from 
IBV-Flagellin-SAPN immunized chickens had a significantly higher stimulation index (3-fold) 
than did PBMCs from chickens receiving Flagellin-only SAPN. Chickens immunized with IBV-
Flagellin SAPN had a significant reduction of tracheal virus shedding and less tracheal lesions than 
did negative control chickens. The data demonstrated IBV-Flagellin SAPN is a promising vaccine 
prototype for IBV. 
5.1 Introduction 
Infectious bronchitis (IB) is a highly contagious avian disease. IB leads to tremendous 
economic losses in the poultry industry. Commercial losses are mainly due to decreased weight 
gain, egg production, and eggs quality (137). Infectious bronchitis virus (IBV), the causative agent 
of IB, belongs to the genus gamma coronavirus, and the order Nidovirales (136). In addition to 
causing respiratory disease and reproductive system defects in chickens, some nephrotoxic IBV 
strains also affect the renal system and cause nephritis (139). Infection with IBV is complicated 
when an opportunistic pathogen like E. coli is present (141).  
Vaccination is considered a major approach in controlling IBV. Both live attenuated and 
inactivated virus vaccines are used to protect chickens against IB. However, limitations of live 
attenuated IBV vaccines include; reversion to virulence, tissue damage which can lead to secondary 
bacterial infections, in addition to interference by maternally derived antibodies diminish its 
efficacy (361).  Moreover, the possibility of recombination between virulent strains and vaccine 
strains, may lead to the development of new pathogenic variants of IBV (251, 362, 363). On the 
other hand, the inactivated vaccines require priming with live attenuated vaccines, multiple 
vaccinations, or large doses of adjuvants due to its shorter immune responses (260, 364).  This may 
elevate the costs of vaccine production and limit its applications (365).  Although DNA vaccines 
offer a novel method of immunization and can induce a cytotoxic T cell response, the low efficiency 
of the vaccine limits its application (265). Synthetic peptide vaccines alone are not immunogenic 
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enough and require co-administering adjuvants (327).  Thus, there is demand for safe and more 
effective vaccines to control IB.  
Lately, there is an increasing interest directed towards the use of nanoparticles as vaccines 
against infectious pathogens (245, 246, 277, 284, 285, 294, 366, 367). These vaccines mimic 
various properties of viral pathogens, including size, and molecular configuration and the ability to 
induce both cellular and humoral immunity (320). Self-Assembled Protein Nanoparticles (SAPNs) 
represent a novel nanoparticle vaccine platform comprised of protein monomers that are capable 
of self-assembling into structures that mimic the size and shape of small viruses (245, 246, 277, 
284, 294). In recent years, we demonstrated the potential of SAPNs as a platform for vaccine 
design, and successfully developed a potent vaccine prototype for Severe Acute Respiratory 
Syndrome (366), HIV (284), toxoplasmosis (294), malaria (285, 368) and Influenza (245, 246).  
SAPNs have many advantages in vaccine delivery over traditional methods. They can repetitively 
present epitopes displayed on its surface by co-expressing at the N or C terminus of a coiled-coil 
monomer. Most importantly, the presentation is conformation-specific (245, 246, 277).  Antigenic 
sequences can be rapidly modified depending on circulating pathogen sequences and easily scaled-
up. Additionally, a new approach of incorporating flagellin, a pathogen associated molecular 
pattern (PAMP) into the SAPN can generate a self-adjuvanted vaccine formulation (246).  
In the present study, we use self-adjuvanted SAPNs as the base for the delivery of an 
antigenic peptide of IBV as model system for the development of a new vaccine platform.   IBV 
has a positive, non-segmented, single-stranded RNA genome of 27-32kb, coding for four structural 
proteins, Spike glycoprotein (S), Matrix or membrane protein (M), Envelope protein (E) and 
Nucleocapsid (N) (148). The spike protein plays an essential role in attachment, virus-cell 
membrane fusion and host specificity during IBV infection.  The IBV spike protein is a class I 
fusion protein which is characterized by formation of an α-helical coiled-coil structure (369). It 
consists of two subunits of S1 and S2, which are in the outer membrane and anchored in the viral 
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enveloped membrane respectively. The S1 subunit is hypervariable whereas the S2 subunit is 
relatively conserved (150). S1 induces neutralizing and serotype-specific antibodies, which show a 
lack of cross protection amongst different strains (152).  S2 subunit contains two heptad areas that 
contribute to the fusion process(370). Because IBV S proteins are the most significant antigenic 
elements to induce neutralizing antibody, IBV vaccine studies have focused on the S protein(261, 
371, 372).  
In a previous study, we reported that a recombinant DNA vaccine carrying IBV S protein 
with chicken interferon protected chickens against challenge with Massachusetts 41 (M41) field 
type IBV (372). Also, we have successfully designed a prototypic vaccine for SARS virus, which 
also belongs to the Coronaviridae family having a high degree of homology with IBV Spike 
glycoproteins. It has been shown that the heptad repeats coiled coils (HRC) sequences of the SARS’ 
coronavirus S protein presented by SAPNs induces strong neutralizing antibodies against SARS 
virus as tested in an in vitro infection inhibition assay (366). Accordingly, in this study we 
investigate the possibility of using the self-adjuvanted SAPN platform to present the HRC sequence 
of IBV’s S protein to develop a novel nanoparticle vaccine formulation to control IBV. 
5.2 Methods and Materials 
5.2.1 Gene synthesis and protein expression of SAPN monomer 
 SAPN monomers were designed containing a pentameric and a trimeric coiled coil region 
held together by a linker. One monomer (Figure 5.1 A:monomer A ) was designed with the 
immunogenic domains of the IBV-M2118 strain S protein on the C terminus which we called IBV 
SAPN monomer, while the second contained the D0-D1 domains of flagellin in place of the IBV 
antigen (Figure 5.1 B monomer B) named flagellin-only SAPN monomer.  To render the 
nanoparticle more immunogenic, two CD4+ epitopes AKFVAAWTLKAAA and 
HAAHAAHAAHAAHAA were engineered into the scaffold of the SAPN.  Genes for both 
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monomers were designed, codon optimized for expression in E. coli, and expressed by 
GenScriptUSA (Piscataway, NJ).  
 
5.2.2 Protein purification 
 Expression and purification was carried out as previously described (246). Briefly, protein 
was expressed in BL21 (DE3) pLys in a 1 L LB culture supplemented with ampicillin (200 µg/mL) 
and chloramphenicol (30 µg/mL). Expression was induced by adding 1 mM isopropyl β-D-
thiogalactopyranoside when culture reached an OD600 of 0.8. After 4 h of incubation, cultures 
were pelleted. Pellets were re-suspened in 8M urea, 100 mM NaH2PO4, 20mM Tris base, pH 8.0, 
then lysed by sonication. Cleared lysate was then used for Immobilized Metal Affinity 
Chromatography. Purification was done using a 5 mL HisTrap HP column in an ÄKTApurifier 100 
(GE Healthcare, Piscataway, NJ). Several buffer gradients were used, including binding buffer 
pH8.0 (8M urea, 100 mM NaH2PO4, 20 mM imidazole, 20mM Tris base), washing buffer gradients 
pH 8.0, 6.5, 5.5, and 4.5 (8M urea, 100mM NaH2PO4, 20 mM sodium citrate). Target protein was 
eluted by 500mM imidazole gradient. Purified protein was analyzed by SDS-PAGE as well as 
underwent dialysis overnight in pre-folding buffer (8 M Urea, 50 mM NaCl, 20 mM Tris, 5% 
Glycerol pH 8.0).   
5.2.3 SAPN refolding and co-assemblies of IBV-flagellin SANP and Flagellin-SAPN  
The protein concentration was determined by NanoDrop 2000 (Thermo Scientific, 
Wilmington, DE). To generate Self-Adjuvanted SAPNs (IBV-flegellin SAPN) a molar 
ratio of 58: 2 IBV-SAPN monomers to Flagellin-SAPN monomer, was established based 
on protein concentration. After establishment of the molar ratios, SAPNs were refolded in 
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a stepwise manner slowly removing urea with stepwise dialysis using Urea-gradient 
buffers- 8M, 6M, 4M, 2M, 120 mM Urea in 20 mM Tris, 5% glycerol pH 8.0, allowing. Final 
buffer concentration was 120 mM Urea, 20 mM Tris Base, 5% glycerol with pH 8.5. 
5.2.4 Dynamic light scattering 
SAPN was analyzed as previously described(246). The SAPNs hydrodynamic diameter 
was measured by DLS at 25ºC, and presented as the average of five runs. SAPNs were absorbed 
on a carbon coated grid, stained with 0.5% uranyl acetate, and imaged using a FEI Tecnai 12 
G2 Spirit BioTWIN.  
5.2.5 Transmission electron microscopy 
Samples were adsorbed onto carbon coated grids (Electron Microscopy Sciences Inc., 
Hatfield, PA) that were subjected to a 30s-glow discharge, washed with distilled water three times, 
and negatively stained with 0.5% uranyl acetate (Electron Microscopy Sciences Inc., Hatfield, PA). 
Electron micrographs were taken on an FEI Tecnai T12 Transmission Electron Microscope.    
5.2.6 Animals, Immunization, virus and challenge 
Four-week-old SPF white Leghorn chickens (n=5) (Charles River laboratories, CT, USA) 
were given intramuscularly 200µL vaccine formulation containing 100 µg IBV-flegellin SAPN.  
Each animal received 3 doses at 9 day intervals. Chickens were bled once before vaccination and 
bled 3 times at 9 days after each immunization. As negative controls, Flagellin-only SAPN, or 
refolding buffer was used to immunize chicken (5 chickens for each group) with the same 
immunization protocol. Chickens at eight-weeks of age were challenged intranasally with 5x104.7 
EID50 IBV M41 strain per chicken. Chickens were observed for 4 days and euthanized 4 days post 
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challenge. Tracheal swab samples were collected at 2 and 4 days post challenge. Blood was 
collected and sera were stored at -80 °C until tested. Handling of chickens was strictly in accordance 
with the protocol (A15-001) approved by the Institutional Animal Care and Use Committee of 
University of Connecticut, Storrs, CT, USA.  Chickens were housed in cages in accordance with 
Ag Guide (2010). Chickens had ad libitum access to water and feed, and were monitored daily by 
attending veterinarians during the study. Any chicken showing lacking of interest in food and water, 
difficulty in breathing, or depression were brought to the attention of the veterinary staffs at animal 
care office.  
5.2.7 Enzyme-linked Immunosorbent Assay (ELISA) 
ELISA plates (Thermo Scientific) were coated with 50 µL of 1 µg/mL either IBV-Flagellin 
SAPN or RBD IBV-SAPN in carbonate-bicarbonate buffer overnight at 4 °C. Plates were blocked 
with 100 µL of 3% BSA in PBST solution (PBS plus 0.05% Tween 20). Serial diluted sera starting 
at 1/100 were incubated in the plates at room temperature for 1 hour. Mouse anti-chicken Ig Y 
followed and incubated in the plates at a 1/1000 dilution at room temperature for 1 hour. 50 µL 
TMB (Thermo scientific) was applied to develop plates at room temperature for 5-15 minutes until 
color developed.  Reactions were stopped with 0.01M HCL. Plates were read for absorbance of 
optical density at 450nm. 
5.2.8 Virus neutralization in embryonated eggs 
Anti-sera collected from vaccinated chickens were mixed with 100 EID50 IBV M41 and 
incubated at 37°C for 1 hour. Virus-sera mixtures were inoculated into allantoic sacs of 9-11 days 
old embryonated SPF eggs (Charles River). Inoculated eggs were incubated for 8 days. Allantoic 
fluid was harvested for RNA extraction with Qiagen viral RNA mini kit under manufacturer’s 
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instruction. Embryos were weighted according to Kapczynki et al(373).  Viral copies of IBV M41 
were quantified using real time RT-PCR.  
5.2.9 Quantification of viral copies by real time RT-PCR 
First strand cDNA in a reverse transcription reaction (RT) was synthesized using Applied 
Biosystem kit. Six hundred eighty ng of total RNA was used in a 20µL reaction containing 0.8µL 
dNTP, 2 µL reaction buffer, 2 µL random primer and 1 µL enzyme mix according to the 
manufacturer’s instruction. RT reaction was conducted in a thermocycler with a programmed 
profile of 26 °C for 10 min, 42 °C for 45 min, 75 °C for 10 min and 4 °C-∞. Real time RT-PCR 
was performed as described in Fan et al, 2012 (25). Reaction mix was prepared with components, 
including 10 µL master mix (SYBR green PCR master mix, Applied Biosystem), 0.25 µL of 25pM 
forward and reverse primers (F: ACAGGTTCTGGTGGTGTTTAGTG; R: 
AGTTGTTCGGGAATGTCTTTGG), 4 µL of cDNA template and 5.5 µL nuclease-free water. 
Reaction was run with in Bio-Rad real time system CFX 96 with a cycling profile, at 94 °C for 2 
min, and 40 cycles at 94 °C for 20 s, 60 °C for 20 s, and 72 °C for 15 s. Melting temperature was 
determined from 65 °C to 95 °C with heating ramp of 0.5 °C/s.  
5.2.10 Lymphocyte proliferation 
Peripheral blood mononuclear cells (PBMC) were isolated using gradient centrifugation in 
Histopaque-1077 (Sigma) Briefly, 2 mL of whole blood was mixed with equal amount of 1X PBS 
shaking for 5 min at room temp. Blood-PBS mixture was overlaid on top of equal volume of 
Histopaque-1077 and centrifuged for 30 min at 400 ×g at 20 °C. The opaque interface was collected 
and washed twice with PBS at 300 g for 5 min. Cell pellet was resuspended, stained with trypan 
blue and counted with a hemocytometer.  PBMC concentration was adjusted to 107 cells/mL. 96-
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well cell culture plates were seeded with 100ul PBMCs of each chicken with a concentration of 
2x105 cells/ well in triplicates. Cells were treated with 10 µg/mL Concanavalin A, 10 µg/mL peptide 
nanoparticle constructs and 10 µg/mL UV-inactivated IBV M41 virus, respectively. Plates were 
incubated at 41 °C with 5% CO2 for 48h. The proliferation assay was conducted using Roche BrdU 
colometric ELISA kit. Briefly, BrdU will be added into each well with final concentration at 10 
µM and incubated at 41 °C with 5% CO2 for 21h. Plates were centrifuged at 300g for 10 min. 
Labeling medium was removed by flicking- off plates, which were air-dried in the dark overnight. 
200 µL/well FixDenat was used to fix cells in the plates for 60 min at 15-25 °C. The fix solution 
was removed thoroughly by flicking and tapping. 100µL/well anti-BrdU-POD working solution 
was used to incubate in the microplates for 90 min at 15-25 °C. Plates were washed 3 times using 
PBS. 100µL/well substrate solution was added and incubated at 15-25 °C until color development 
for 5-30 min. Reaction was stopped by adding 25 µL 1M H2SO4 to each well. Absorbance was 
measured at 450nm with background reference wavelength 690nm. Stimulation index was 
calculated by the formula, SI=OD value (antigen-stimulated PBMCs)/OD value (medium treated 
PBMCs).  
5.2.11 Histopathologic analysis 
Tracheal tissues were harvested postmortem at 4 days post challenge, and fixed in 10% 
neutral formalin. Hematoxylin and eosin staining was performed on the cross section of tracheal 
tissues. Scoring scale was established with modification as previously described by Grgiæ et al, 
2008 (26). Score 0: no lesions; Score 1: mild epithelial hyperplasia, lymphoid infiltration and loss 
of cilia; Score 2: moderate epithelial hyperplasia, complete loss of cilia, pronounced edema of the 
lamina propria; Score 3: severe epithelial hyperplasia, severe subepithelial lymphocyte infiltration, 
prominently increased thickness of mucosa, disappearance of mucosal gland and severe 
hemorrhage.  
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5.2.12 Statistical analysis 
Data was analyzed using one or two-way ANOVA with Bonnferoni post-test in Graphpad 
prism 6.0. Statisctical significance were achieve at levels of P values <0.05 (*), <0.01 (**), and 
<0.001 (***). 
5.3 Results 
5.3.1 Synthesis and biophysical characterization of nanoparticles 
Three fusion genes encoding SAPN core and epitope sequences were successfully 
synthesized and sub-cloned into plasmids (Figure 5.1). SDS-PAGE of refolded SAPNs revealed 
that IBV-Flagellin SAPN and Flagellin-SAPN showed optimal purity and expected molecular 
weights (Figure 5.2). Dynamic light scattering was showing hydrodynamic diameters 45.77nm and 
32.83nm for IBV-Flagellin SAPN and Flagellin-only SAPN, respectively, which were confirmed 
by transmission electron microscopy showing a well-formed shape at nano scale (Figure 5.3). They 
are optimal enough to be used as immunogens.    
		 101 
5.3.2 Chickens vaccinated with IBV-flagellin SAPN elicited high level of antibody responses 
To test for antibody responses elicited by the SAPNs, ELISA was performed using 96-well 
plates coated with 10 µg/mL of synthetic HR2 peptide. The results show markedly elevated 
antibody responses in chickens vaccinated with IBV-Flagellin SAPN (Figure 5.4 C) while 
Flagellin-only SAPN and buffer immunized chickens’ groups had no detectable antibody response 
(Figure 5A, B). A clear booster effect was observed in chickens vaccinated with IBV-Flagellin-
only SAPN as indicated by elevations of antibody level after each dosage (Figure 5.4 C). These 
results demonstrated that IBV-Flagellin SAPN vaccine induced humoral immune responses in 
chickens.  
5.3.3 Sera induced by IBV SAPN neutralized infection of IBV M41 in chicken embryos 
To determine the presence of neutralizing antibodies, virus neutralization was performed 
by the inoculation of 100 EID50 IBV virus/anti-sera mixture into embryonated eggs. Positive virus 
neutralization is manifested by the prevention of weight loss of embryos, and the attenuation of 
signs of dwarfing caused by the IBV infection as well as manifested by the reduction of viral load 
in the allantoic fluid of the treated embryos. As shown in Figure 5.5, hyperimmune sera against 
IBV prominently neutralized the infection by IBV M41 in embryos, showing normal weight (Figure 
5.5A), normal growth (Figure 5.5C) as healthy embryos, and lower viral load present in the 
allantoic fluid (Figure 5.5B) as compared to the embryos which received negative sera/virus 
mixture or IBV M41 alone that showing weight loss, stunting and higher viral loads. Regarding our 
test sera collected from chickens with or without inoculations of a vaccine, we only found a 
neutralization effect in sera harvested from chickens only after primary immunization showing gain 
of embryo weight, attenuated signs of disease and lower viral load while comparing to sera from 
buffer-inoculated chickens (Figure 5.5). This result is consistent to the test positive control of 
hyperimmune sera against IBV.  
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5.3.4 SAPN or IBV significantly stimulated immune recall in PBMCs from chickens 
vaccinated with IBV-Flagellin SAPN 
Immune memory induced by vaccine immunogens could be indicated by the proliferation 
of PBMCs triggered by the exposure of the immunogen or the target pathogen containing the 
vaccine epitope. To determine an SAPN or IBV virus- induced proliferation in vitro, PBMCs were 
isolated from negative control or immunized chickens after 9 days post- second booster 
immunization of IBV-Flagellin SAPN or Flagellin-only SAPN, respectively. They were stimulated 
in vitro either with 100 µg inactivated IBV M41 virus or were pulsed with 10µg/mL correspondent 
SAPN.  As shown in Figure 5. 6, PBMCs from groups of chickens immunized with IBV-Flagellin 
SAPN following stimulation of SAPN or IBV virus showed significantly higher proliferation than 
in the negative control group vaccinated with flagellin-only SAPN, demonstrating the capability of 
immune recall induced by the immunogens.  
5.3.5 Chickens vaccinated with IBV-flagellin SAPN significantly reduced shedding of IBV 
viruses in tracheas  
To evaluate the vaccine potency of restricting virus replication, viral shedding from 
tracheas in immunized or negative controls chickens after challenge with IBV M41 was determined 
by real time RT-PCR. The IBV-Flagellin SAPN vaccine group had lower levels of tracheal 
shedding of IBV than the buffer-inoculated control group at 2 and 4 days post challenge (Figure 
5.7A). A significant reduction of virus shedding in tracheas was found at 2 and 4 days post 
challenge as compared to Flagellin-only SAPN and Buffer groups (Figure 5.7A). Interestingly, 
chickens inoculated with a negative control construct, Flagellin-only SAPN, also had lower level 
of virus shedding than the buffer inoculated group. A significant reduction of virus induced by 
Flagellin-only SAPN was found at 2 days post challenge (Figure 5.7A). To rule out the inference 
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of non-infectious virus on the result, we also recovered infectious IBV from the swab samples, by 
inoculating embryonated eggs, and quantified the RNA copies of the recovered virus by real time 
RT-PCR. Similarly, we found the level of infectious virus recovered from SAPN groups was lower 
than the buffer control group, indicating the restriction of virus replication in chickens by SAPN 
treatment (Figure 5.7B). Significantly lower viral load was observed in IBV-Flagellin SAPN group 
at 2 days post challenge compared to buffer control or Flagellin-only SAPN groups (Figure 5.7B). 
These observations demonstrated the prophylactic potential of the prototypic IBV-Flagellin SAPN 
vaccine. 
5.3.6 Chickens vaccinated with IBV-Flagellin SAPN had significantly less histopathological 
lesions in tracheal tissues than no vaccine group 
The restriction of progression of disease is a direct indicator of the prophylactic effect of a 
tested vaccine candidate. To evaluate the vaccine-induced protection, we scored the histopathologic 
lesions in tracheal tissues at 4 days post challenge with four grading scales (Figure 5.8 A, B, C and 
D). IBV-Flagellin SAPN or Flagellin-only SAPN group had significantly less tracheal lesions than 
the buffer control group (Figure 5.8 E). Additionally, chicken vaccinated with IBV-Flagellin SAPN 
had lower pathologic scores than Flagellin-only SAPN group (Figure 5.8 E). These results were 
consistent with the virus shedding in the trachea, suggesting the protective efficacy of our IBV-
Flagellin SAPN vaccine. 
 5.4 Discussion 
Vaccination has been largely used to control IBV for 50 years. However, a challenge 
remains because currently available live attenuated or killed vaccines are not effective to combat 
rapidly emerging variant strains generated from point mutation or recombination. In addition, live 
attenuated vaccines are still the predominant vaccines in use, and their use raises the concern of 
safety (138, 147) as they contribute to the emergence of new pathogenic IBV variants (251). Peptide 
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subunit vaccines offer a safer profile, but are usually poorly immunogenic when used alone (327). 
Nanoparticle has been demonstrated as a promising delivery system to improve drug efficacy. 
Nevertheless, there are still some issues challenging the development of nanoparticle as a vaccine 
delivery system. On one hand, cell toxicity of some nanoparticles is a major problem that challenges 
its development, such as titanim oxide, gold, cationic lipid(374-377). On the other hand, it is 
difficult to maintain antigen stability and correctly display antigen conformation on the surfaces of 
some nanoparticles(280). 
In contrast, SAPNs have been demonstrated as an innovative method in vaccine design that 
repetitively display antigenic epitopes in their native conformation, which are successfully applied 
to design vaccines inducing robust immune responses against numerous pathogens including 
malaria, influenza, SARS, toxoplasma and HIV(245, 246, 277, 284, 294, 366).  
In the present study, we have developed an IBV SAPN vaccine candidate that repetitively 
presents IBV antigens. This vaccine also contains the D0-D1 domains of flagellin to self-adjuvant 
the vaccine and increases its immunogenicity. We successfully applied this system for influenza, 
suggesting a significant improvement of immunogenicity in terms of antibody response against 
avian and human influenza viruses(245, 246). In the current study, we expanded our self-
adjuvanted SANP technology for use in avian infectious bronchitis.  
IBV coronavirus S protein is considered to be the main antigen and therefore mainly used 
to induce protection against coronaviruses(152, 378, 379). Several studies have suggested that the 
manipulated S protein could serve as major target for the vaccine design against coronaviruses 
(372, 380-384).  The HR region of coronavirus S protein is an α-helical trimeric coiled-coil(385). 
Therefore, a peptide vaccine that displays HR in its trimeric coiled-coil conformation would be 
ideal.  Our previous research showed that a self-assembling polypeptide nanoparticle that 
repetitively displays a SARS B-cell epitope from the C-terminal HR of the virus’ spike protein was 
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able to neutralize SARS-Coronavirus infectivity. In this study, SAPNs that repetitively displays 
HR2 of IBV S protein induced noticeably high level of antibody responses. This result demonstrates 
that our IBV-Flagellin SAPN prototype nanoparticle vaccine was able to induce protective humoral 
immune responses in chickens.  Repetitive presentation of B cells epitope is essential to enhance 
humoral immune response as they cross-link B cell receptors and activate B cell response(136, 
386). In this study, we were able to repetitively present HR2 in its native trimeric conformation.  
Furthermore, the vaccine candidate significantly stimulated immune memory in PBMCs from 
chickens, which suggest that it can potentiate a chicken cellular immune response. 
In current study, challenge revealed that protection was higher in the group of chickens 
vaccinated with IBV-Flagellin SAPN than that in control groups.  A significant reduction of viral 
RNA load in tracheas was found at 4 days post challenge as compared to control groups. This was 
consistent with tracheal histopathological scores which indicated that chickens vaccinated with 
IBV-Flagellin SAPN had significantly less tracheal histopathological lesions than control groups. 
On the basis of the viral RNA load in the trachea and tracheal histopathological assessments, IBV-
Flagellin SAPN vaccine can protect chickens from challenge with IBV M41 without co-
administration of commercial adjuvants.  
In the current study, we added flagellin as an immunostimulatory molecule to the SAPN to 
generate a self-adjuvanted SAPN. Flagellin has been extensively explored for the use as an adjuvant 
in various kinds of vaccine formulations, including soluble mixture with proteins, co-expressed 
with epitopes or encoded in DNA vaccines (387-389).  It is interesting that the Flagellin-only SAPN 
is able to significantly reduce viral shedding in trachea of inoculated chickens after challenged with 
IBV (Figure 5.7). Chickens inoculated with Flagellin-only SAPN also had significantly less 
pathologic scores in tracheal tissues than chickens inoculated with buffer (Figure 5.8E). The 
protective effect of Flagellin-only SAPN may be attributed to the non-specific activation of nature 
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killer cells and macrophages, and to the recruitment of heterophiles, which lead to the limited 
restriction of virus replication. These observations are in accordance with the fact that flagellin can 
induce   pro-inflammatory cytokines accounting for an antiviral effect. However, protection with 
the IBV-Flagellin SAPN vaccine was significantly higher than that of Flagellin-only SAPN based 
on both parameters.  These data suggested that we have successfully implemented a self-adjuvanted 
SAPN for the use as a vaccine against IBV.   
5.5 Contributions 
Dr. Peter Burkhard designed all SAPNs. Dr. Christopher Karch produced and physically 
characterized all SAPNs in Dr. Peter Burkhard’s laboratory. Jianping Li performed all in vitro and 
in vivo studies to evaluate the efficacy of SAPN vaccine candidates using a chicken model. 
 
Figure 5. 1 Peptide sequences of monomeric building blocks of SAPN for IBV.  
The monomer A will be used to build vaccine prototype ‘RBD-IBV SAPN’.  Monomers B & C 
will be co-assembled at molar ratio of 58: 2 to refold into ‘IBV-Flagellin SAPN’; Monomer C will 
be used to assemble into a SAPN devoid of IBV eptitope-‘Flagellin-only SAPN’ that will serve as 
negative control. Color scheme: Red, receptor binding sequence in monomer A and malaria B cell 
epitope in monomer B; Gold S1 epitope in (A); Green: a pantameric coiled-coil; Teal: trimeric 
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coiled-coil; Blue: HR2 B cell epitope; Black: linked Sequence; Pink: CD4 T cell epitope 
(AKFVAAWTLKAAA; HAAHAAHAAHAAHAA); Purple: The sequence of flagellin D1 and D2 
domains. 
 
 
 
 
 
Figure 5. 2 SDS-PAGE of refolded IBV SAPNs.  
A: co-assembles of IBV SAPN, IBV-Flagellin SAPN and Flagellin-only SAPN (orange arrows). 
1, IBV SAPN assembled from monomer A; 2, IBV-Flagellin SAPN assembled from monomer B 
and C at 58:2 molar ratio; 3, Flagellin-only SAPN assembled from monomer C. B: purification of 
RBD-IBV SAPN showing multiple forms of oligomers (orange arrows). 1, bacterial lysate; 2, 
flow-through; 3, fraction before elution; 4, fraction after elution. 
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Figure 5. 3 Characterizations of SAPNs by DLS and TEM. 
A: IBV-Flagellin SAPN by DLS; B: Flagellin-only SAPN by DLS. C: IBV-Flagellin SAPN by 
TEM; D: Flagellin-only SAPN by TEM.   
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Figure 5. 4 antibody responses in immunized chickens by ELISA. 
A: serial diluted sera from chickens inoculated with buffer; B: net results after the subtraction of 
antibody response against the flagellin sequence for the serial diluted sera from chickens 
immunized with IBV- Flagellin SAPN; C: net results after the subtraction of antibody response 
against the coiled-coil sequence using serial diluted sera from chickens vaccinated with RBD IBV-
SAPN. D: serial diluted sera from chickens vaccinated with flagellin-only SAPN raised against 
plates coated with IBV-Flagellin SAPN. E, serial diluted sera from chickens vaccinated with RBD 
IBV-SAPN raised against plates coated with flagellin-only SAPN. 
 
 
		 110 
  
 
Figure 5. 5 Virus neutralization in embryonated eggs.  
A: weight loss; B: viral load in allantoic fluid quantified by real time RT-PCR; C: clinical signs of 
embryos.  
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Figure 5. 6 Lymphocyte proliferations.  
PBMCs harvested from SAPN-immunized chickens were stimulated with SAPNs or IBV virus and 
cultured for 72 hours. Proliferation of lymphocytes was measured using colormertric ELISA assay. 
Stimulation index was calculated as described above. A: PBMCs were pulsed with respective 
SAPN at final concentration of 10 µg /mL; B: PBMCs were pulsed with killed IBV virus.  
 
  
Figure 5. 7 Viral shedding in chicken tracheas and virus recovery from tracheal swabs.  
A: tracheal swab sample were used to extract RNA that was quantified by real time RT-PCR; B: 
Virus was recovered and isolated by inoculating tracheal swab sample into embryonated eggs. 
Recovered virus was quantified by real time RT-PCR.  
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Figure 5. 8 Evaluation of histopathologic lesion in tracheal tissues.  
A, normal tracheal tissue; B: representative tracheal tissue from chickens inoculated with buffer; 
C: representative tracheal tissues from chickens inoculated with Flagellin-only SAPN; D: 
representative tracheal tissues from chickens inoculated with IBV-Flagellin SAPN; E: 
histopathologic scores. 
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Chapter 6 Discussion and Conclusions 
6.1 Discussion 
6.1.1 SAPN vaccine prototype for AI 
The development of a universal vaccine against influenza has been challenging. The protective and 
immunodominant epitopes presented upon influenza infection or upon seasonal influenza 
vaccination are hypervariable. Seasonal influenza vaccines fail to prevent influenza over multiple 
seasons because of antigenic drift and shift. The hurdle created by sequence diversity could be 
overcome by the induction of protective antibodies against conserved antigens, such as M2e and 
the stalk–derived HA Helix C. Antibodies against these regions were previously found to be 
protective(287, 390, 391), suggesting that the development of a universal vaccine is indeed 
possible. To elicit highly protective antibodies using M2e and Helix C for immunization, it is 
critical to present these antigens in their native conformation with the correct oligomerization state. 
Furthermore, a high titer of antibodies with high avidity is needed for efficient protection. We have 
successfully addressed these critical issues in our study. 
Subunit vaccines offer numerous advantages including increased specificity, better safety 
profiles, as well as decreased manufacturing costs. The major weakness of subunit vaccines is that 
they tend to be less immunogenic than whole organism vaccines. By developing our new self-
adjuvanted SAPN technology, we have addressed this issue in two different ways. First, the SAPNs 
are repetitive antigen displays that have been previously shown to increase immunogenicity. 
Second, by adding flagellin to generate self-adjuvanted SAPNs, we were able to improve the 
overall immunogenicity in terms of antibody titer compared to conventional SAPNs. A very crucial 
aspect besides the repetitive display of antigens is that we can display our immunogens on our 
SAPNs in their native conformation and oligomerization state such as M2e as a tetramer and Helix 
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C as a trimer. A further advantage of our SAPN technology is the display of two different antigens 
that will result in two different means of protection. M2e protection is ADCC-based(307, 392), 
while Helix C induces virus-neutralizing antibodies. 
Today's licensed trivalent influenza vaccines poorly induce M2e- or Helix C–specific 
antibodies, in contrast, M2e- and Helix C–specific antibodies are induced upon immunization with 
live-attenuated virus vaccine or upon recovering from an influenza infection(393). The low 
antigenicity of M2e or Helix C is thought to be due to immunodominance of the hemagglutinin 
globular head and the poor presentation of these domains at the virus surface. The question remains 
though, why increased antigenicity of M2e or Helix C is observed upon influenza infection or upon 
live-attenuated virus immunization. We suggest a very short time frame of accessibility of the M2e 
and Helix C domain as a consequence of conformational changes of hemagglutinin during host cell 
invasion process. The short accessibility underlies the importance of high titer of M2e and Helix C 
antibodies in order to provide efficient protection. 
We have demonstrated that self-adjuvanted SAPNs bearing flagellin of 3% molarity fold 
into similar sized and shaped particles as conventional SAPNs, that these particles are able to 
stimulate TLR5 signaling in vitro in a dose- and concentration-dependent manner. SAPN-bound 
flagellin is more effective to activate TLR-5 than did free recombinant form. This observation is 
consistent with previous reports that polymerized form TLR ligands stimulate comparable or higher 
levels of prolonged innate immunity than do the free soluble form of the ligands(311, 394, 395). 
This result suggested that SAPN-bound flagellin could be an alternative to the soluble recombinant 
flagellin, which is costly. SAPN technology may also be extended to display other proteinaceous 
immunostimulatory molecules for the development of next generation adjuvants. 
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  Self-adjuvanted SAPNs induce significantly higher levels of antibodies in vaccinated 
animals and those antibodies are over 50% more efficient at neutralizing H5N2 in an in vitro 
infection model than antibodies from SAPN-vaccinated animals alone. The induction of broadly 
neutralizing antibodies against heterologous subtypes of influenza viruses was also demonstrated. 
Upon challenge with highly pathogenic (HP) AIV, 63 % and 30% of chickens the SAPN IM and 
SAPN ED vaccine groups, respectively, survived. A reduction in challenge virus shedding from 
oropharyngeal swabbing of the SAPN IM vaccinates was observed on days 2 and 14-post challenge. 
These results show the SAPN vaccine prototype was partially protective against HP AIV lethal 
challenge. To screen a SAPN compatible adjuvant in addition to the self-adjuvanted SAPN, a broad 
range of adjuvants were examined, including unmethylated cytosine-guanine dinucleotide-
containing oligodeoxynucleotides (CpG ODN) (Invivogen, ODN2006), MONTANIDETM IMS 
1313 VG N (IMS), MONTANIDETM GEL 01 (Gel) and Monophosphoryl Lipid A (MPLA). Only 
have MPLA of low dosage at 0.2 µg demonstrated it was compatible and potent to enough to 
enhance the immunogenicity of our SAPN vaccine SA-MC-Penn (Figure 4.1, 4.2 and 4.3), 
indicated by elevated production of antibodies and reduction of virus shedding in a LPAI challenge 
model. 
These data indicated an initial successful implementation of the self-adjuvanted SAPN 
technology for designing a universal influenza vaccine candidate. To eventually become an 
alternative vaccine to current AI vaccines, more future works are required to improve the 
immunogenicity of the current SAPN vaccine candidate SA-MC-Penn. First of all, more antigenic 
B cell epitopes should be explored using self-adjuvanted SAPN technology. SA-MC-Penn didn’t 
confer complete protection against HPAIV challenge, suggesting the ADCC response by M2e and 
neutralizing antibodies induced by Helix C may not potent enough to restrict virus replication. The 
mechanism of a protection conferred by HA stalk-derived antibodies is through intercellular 
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blocking of the membrane fusion between the virus and the endosomal membrane and extracellular 
inhibition of proteolytic activation of HA(310). Because the time frame of accessibility of the M2e 
and Helix C domain may be very short as a consequence of conformational changes of 
hemagglutinin during the host cell invasion process, it requires a very high concentration of 
internalized antibodies of anti-M2e or anti-Helix C antibodies. There might not be sufficient 
antibody bound to the viruses co-transporting into host cells during infections. These reasons might 
account for only a partial protection against HPAI challenge in our study. Antibodies blocking viral 
entry are a major class of neutralizing antibodies induced by native AI HA protein. Yet, Anti-M2e 
or anti-Helix C is not able to block the entry of AI virus into host cells. A B cell epitope inducing 
antibodies to block the receptor binding during virus entry could be an effective option. It has been 
reported that monoclonal antibodies bound to the receptor-binding site on the head of HA showed 
very potent virus neutralization, such as CH65, 5J8, CR8033, and C05(315, 396). Therefore, the 
conserved receptor-binding site could be considered for future design of SAPN vaccine. Second, 
it’s necessary to determine the antigenicity of the D0 and D1 domains of flagellin in our SAPN. 
The question of whether the flagellin domains distract from the immune responses to the target 
antigens M2e or Helix C must be addressed. Third, the suppression of virus shedding by SA-MC-
Penn in chickens was not pronounced enough in both our LPAI and HPAI challenge studies. It 
suggested it is necessary to design a SAPN vaccine inducing antigen-specific CD8+ T cell 
responses against AI for the clearance of viruses. Fourth, incorporating an epitope inducing 
mucosal IgA responses against AI might be also important because AIV is a mucosal pathogen and 
mucosal IgA has been demonstrated as the most effective class of antibodies to restrict mucosal 
pathogens. Fifth, testing a polymerized form of MPLA as use in SAPN vaccine. 
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6.1.2 SAPN vaccine prototype for IBV 
Vaccination has been largely used to control IBV for 50 years. However, challenge still 
remains because currently available vaccines of live attenuated or killed vaccines are not effective 
to combat rapidly emerging variants of virus strains generated from point mutation or 
recombination. In addition, live attenuated vaccine is still the predominant kind, and its usage raises 
the concern of safety(138, 147). Peptide subunit vaccine offers a safer profile but usually is poorly 
immunogenic when used alone(327). Upon the initial successful design of the self-adjuvanted 
SAPN vaccines for AI, we have applied the SAPN technology to design vaccine prototypes for 
IBV. Our IBV vaccine prototypes have been demonstrated to induce high levels of antibody 
responses (Figure 5.4 C), significantly potentiate immune memory (Figure 5.6 A and B), and 
significantly reduced tracheal virus shedding 2 and 4 days post challenge with a field strain of IBV 
M41. Lower histopathologic scores were observed in the vaccine group than in the control group 
(Figure 5.8 A-E). 
Interestingly, immunization of a Flagellin-only SAPN without IBV epitope in chickens 
showed a prophylactic effect against IBV challenge, indicated by significant lower virus shedding 
at day 2 after challenge (Figure 5.7A) and lower tracheal lesion scores (Figure 5.8 E) as comparing 
to chickens receiving buffered saline alone. The mechanism of the prophylactic effect needs to be 
determined. We did see high antigenicity of flagellin in our IBV-Flagellin SAPN and Flagellin-
only SAPN, and the antigenicity of coiled-coil core sequence in all versions of SAPN, indicated by 
high level of antibody responses were detected in ELISA assays (Figure 5.4 D and E). Those non-
specific immune responses by non-target antigens may distract away from desirable immune 
responses against our target antigens loaded in the SAPN. It suggested the requirement of reducing 
non-specific immune responses to the adjuvant molecule and the scaffold sequences of the SAPN 
core. Although only weak neutralizing antibodies induced by IBV-SAPN were observed (Figure 
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5.5A-C), immunization with our vaccine prototypes in chickens have still achieved some level of 
protection against challenge indicated by reduction of virus shedding (Figure 5.7 A), the limitation 
of virus replication in trachea (Figure 5.7 B), and attenuated tracheal lesions (Figure 5.8 E). We 
speculated the protection might not be conferred by antibody responses, which agreed with the 
previous observation that circulating antibody responses were not correlated to tissue protection 
from IBV infection(190). Instead, local antibody responses were believed to be playing an 
important role in the protection of respiratory tracts against re-infection of IBV virus in chickens, 
mainly attributed to the antibodies produced in the Harderian gland, especially the isotype IgA(194-
196). Since the Ig A response was not examined in this study, we cannot rule out that the protection 
may be conferred by a local IgA response. This requires further determination in future trials. It is 
also important to take the consideration of engineering Ig A-inducing epitopes into future SAPN 
design for IBV. 
6.2 Conclusions 
These data presented in this work indicate that we have initially, successfully designed and 
implemented our self-adjuvanted SAPNs for use as vaccine candidates for avian influenza and 
infectious bronchitis. We have demonstrated self-adjuvanted SAPN vaccine prototypes are 
protective against challenge from AI and IB. It suggested that they could be used as a standalone– 
or possibly even better – as an additional component to an established AI or IB vaccine to broaden 
the protection of the vaccine. Furthermore, with these findings in mind, we can expand our self-
adjuvanted SAPN technology for use in many different diseases that have been traditionally 
difficult to develop effective vaccine candidates for including malaria, tuberculosis, HIV and many 
more. 
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